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1. INTRODUCTION 
 Early in the twenty century herbal medicine was a prime healthcare system as antibiotics 
or analgesics were not available. With the development of allopathic systems of medicine, herbal 
medicine gradually lost its popularity among people and it was based on the fast therapeutic 
actions of synthetic drugs.  Almost a century has passed and we have witnessed limitations of 
allopathic systems of medicine. Lately herbal medicine has gained momentum and it is evident 
from the fact that certain herbal remedies peaked at par with synthetic drugs.  
 It can be concluded that knowledge of Alternative and Complementary Systems of 
Medicines like Ayurveda, botany, pharmacognosy and phytochemistry, biochemistry, ethno 
pharmacology and toxicology is integral part of herbal medicine.  
 Recently we have witnessed explosive growth of herbal drug industry. Data and meta-
analysis have shown that more and more people are consulting herbal practitioners. It‟s cheering 
that the World Health Organization has also identified importance of herbal medicine. According 
to a study from U.S., 60-70% patients living in rural areas are dependent on herbal medicine for 
their day to day diseases. (Singh A; 2007) 
 Several authors have reported favorable results with herbal drugs (mostly in form of 
extracts) either in animal or in human studies. Ginkgo biloba L., Echinacea purpurea L., 
Hypericum perforatum L. and Cimcifuga racemosa (L.) Nutt, were subjected to clinical trials.   
 Silybum marianum L., the reputed hepatoprotective, has remained a golden standard in 
the treated of liver ailments. Several years have passed but status of this herbal drug remains 
unquestioned. In India, a study reported that Picrorrhiza kurroa Royle. Is more potent than 
Silybum marianum as hepatoprotective agent (however, this study is not complete in all aspects). 
(Singh A; 2007) 
 Herbal drugs are significant source of hepatoprotective drugs. Mono and poly-herbal 
preparations have been used in various liver disorders. According to one estimate, more than 700 
mono and poly-herbal preparations in the form of decoction, tincture, tablets and capsules from 
more than 100 plants are in clinical use. Surprisingly, several studies have appeared in journals 
addressing hepatotoxic potential of herbal drugs. These studies suggest that the drugs that were 
claimed to be hepatoprotective are actually hepatotoxic.  
 In India, several steps have been taken to improve quality of Ayurvedic medicines. Good 
manufacturing practice (GMP) guidelines have been introduced so as to ensure quality control. 
Medicinal plant boards have been constituted at state and center level to inspire people, 
particularly the farmers for adopting cultivation of medicinal plants. Herbal gardens have been 
developed to make the common man conversant with the rich heritage of Indian system of 
medicine. Various institutes like NIPER, NBRI, CIMAP and CDRI are playing pivotal role in 
laying down standards for Ayurvedic system of medicine.  
 To conclude it may be said that herbal drugs have provided us with potent weapons like 
atropine, codeine, taxol, vincristine and vinblastine. In the modern scenario, diseases are 
becoming drug-resistant and scientists are studying possible roles of plant based drugs for 
screening life saving drugs. The herbal system of medicine is a fully fledged system of medicine 
and it cannot be ruled out as quackery. Backing up this system is the fact that ancient findings 
and documentation have through the centuries provided us with leads on the development of life-
saving drugs.  
 Treatment options for common liver diseases such as cirrhosis, fatty liver, and chronic 
hepatitis are problematic. The effectiveness of treatments such as interferon, colchicine, 
penicillamine, and corticosteroids are inconsistent at best and the incidence of side-effects 
profound. All too often the treatment is worse than the disease. Conservative physicians often 
counsel watchful waiting for many of their patients, waiting in fact for the time when the disease 
has progressed to the point that warrants the use of heroic measures. Physicians and patients are 
in need of effective therapeutic agents with a low incidence of side-effects. Plants potentially 
constitute such a group. 
 Several hundred plants have been examined for use in a wide variety of liver disorders. 
Just a handful has been fairly well researched. The latter category of plants include: Silybum 
marianum (milk thistle), Picrorhiza kurroa (kutkin), Curcuma longa (turmeric), Camellia sinensis 
(green tea), Chelidonium majus (greater celandine), Glycyrrhiza glabra (licorice), and Allium 
sativa (garlic). This review will be divided into two parts. Silybum marianum and Picrorhiza 
kurroa will be reviewed in Part One. Curcuma longa, Camellia sinensis, Chelidonium majus, 
Glycyrrhiza glabra, and Allium sativa 
There are number of phytoconstituents from plants which have exhibited antihepatotoxic activity 
 A number of recent reviews have focused on the adverse effects of herbal products. In the 
current review, we will highlight on herbs known to be hepatoprotective, mechanisms of 
hepatoprotectivity, and clinical documentation. In fact some herbal products claiming to be 
Hepatoprotective may actually be having some components with hepatotoxic potential. 
 Silybum marianum, Picrrorhiza kurroa, Andrographis paniculata, Phyllanthus niruri, and 
Eclipta Alba are proven Hepatoprotective medicinal herbs, which have shown genuine utility in 
liver disorders. These plants are used widely in Hepatotprotective preparations and extensive 
studies have been done on them. Their discussion is beyond the scope of the article. 
 India is known as a botanical garden in world and the largest producer of herbal 
medicines. India recognizes more than 3000 plant as medicinal use. It is estimated that more than 
6000 plants in India are in use in traditional and herbal system of medicines. Herbal medicines 
are used in various forms in indigenous system such as Unani, Ayurveda, and 
Siddha.(Farnsworth NR et al;1991) 
 Around 25,000 effective herbal formulations are used in traditional and folk medicine in 
India. The demand for plant products is increased throughout the world and the pharmaceutical 
companies are currently carrying out research on plant material for the potential medicinal 
components. Even though they are not able to prove the therapeutic effects of many plants, 
research continues to screen the active ingredients which form the basis of drugs to fight disease 
like psychological disorder, neuro-developmental disorder, diabetes, cancer, AIDS and various 
more chronic disease.(Prakash KC et al;2007) 
  Herbal drug is the oldest form of health care known to mankind. Herbs had been used by 
all the cultures throughout the history. In modern civilization herbal drug is an integral part of 
the development. Primitive man observed and appreciated the great diversity of plants available 
to him. The most use of medicinal plant has been developed through observation of wild animal 
by trials and errors. As time moved on, each tribe added the medicinal power of herbs in their 
area based on their knowledge. They collected the information on herbs based on the method and 
well-defined it in herbal pharmacopoeia. Indeed, well into the 20th century most of the 
pharmacopoeia of scientific medicine was derived from the herbal lore of native place. Much of 
the drug commonly use now a day is of herbal origin. Most civilized country USA dispensed 
about 25% of prescription which contains at least one active ingredient derived from plant 
materials. Some are made from plant extract others are synthesized to mimic the natural plant 
compounds.  
 From last five thousand years human being has relied on natural product as the primary 
source of medicines. However, the last two centuries have brought an explosion to understand 
how the natural products are produced and how they react with other organisms. The World 
Health Organization (WHO) estimates that 80% of the world health populations presently use 
herbal medicines for some aspect of primary health care (Kokate CK et al; 2011)  
 
 In recent years synthetic drugs are showing more adverse affect, to overcome this 
problem researchers are trying to avoid this risk of those drugs. Whenever a drug is prescribed to 
a patient they are facing risk of side effect, so long term use of these drugs patient should be 
careful. But in herbal medicine the toxic effects are negligible, so the uses of herbal industry are 
growing up. Indian, Chinese are using plant as medicine, as whole plant or its extract. Toxicity of 
herbal drugs is less when compared with the synthetic medicines. (Farnsworth NR et al; 1991) 
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2. REVIEW OF LITERATURE 
2.1 Liver 
 The liver is a vital organ only found in vertebrates. The liver has a wide range of 
functions, including detoxification of various metabolites, protein synthesis, and the production 
of biochemical‟s necessary for digestion. It also plays a role in metabolism, regulation of 
glycogen storage, decomposition of red blood cells and hormone production. 
Terminology related to the liver often starts in hepat- from the Greek word for liver 
2.2 Structure 
 A human liver normally weighs 1.44–1.66 kg (3.2–3.7 lb) and has a width of about 15 
cm. It is the heaviest internal organ and the 2
nd
 largest gland in human body. Then it is located in 
the right upper quadrant of the abdominal cavity, it rests just below the diaphragm, to the right of 
the stomach and overlies the gallbladder.  
 Reddish - brown wedge-shaped organ with four lobes of unequal size and shape. 
Functional units of the liver are lobules and it is made up of hepatic cells (hepatocytes) which are 
the basic metabolic cells.  
The liver is connected to two large blood vessels: the hepatic artery and the portal vein 
The lobules are held together by a fine dense irregular fibro elastic connective tissue layer which 
extends into the structure of the liver, by accompanying the vessels (veins and arteries), ducts 
and nerves through the hepatic portal, The whole surface of the liver is covered in a serous coat 
derived from peritoneum and this has an inner fibrous coat (Gilson‟s capsule) to hitch it is firmly 
adhered. The fibrous coat is of areolar tissue and follows the vessels and ducts to support them.  
2.3. Lobes 
 There are, on the surface, four lobes: right, left, caudate and quadrate. The Falciform 
ligament divides the liver into two main lobes, right and left, with the right lobe being the larger 
and is sub- divided into the right lobe proper, the caudate lobe and the quadrate lobe. 
Gross anatomy traditionally divided the liver into two portions – a right and a left lobe, as 
viewed from the front (diaphragmatic) surface; but the underside (the visceral surface) shows it 
to be divided into four lobes and includes the caudate and quadrate lobes. (Erwin k et al; 2009)  
 The falciform ligament, visible on the front of the liver, divides the liver into a left and a 
much larger right lobe. From the visceral surface, the two additional lobes are located between 
the right and left lobes, one in front of the other. A line can be imagined running from the left of 
the vena cava and all the way forward to divide the liver and gallbladder into two halves. This 
line is called "Cantlie's line". 
 Other anatomical landmarks exist, such as the ligamentum venosum and the round 
ligament of the liver (ligamentum teres), which further divide the left side of the liver in two 
sections. An important anatomical landmark, the porta hepatis, also known as the transverse 
fissure of the liver, divides this left portion into four segments, which can be numbered starting at 
the caudate lobe as I in an anticlockwise manner. From this visceral view, seven segments can be 
seen, because the eighth segment is only visible in the parietal view. (Erwin k et al; 2009)  
 
 Fig. No 1: Liver lobes 
 
 
 
2.4. Facts about liver 
 The liver performs over 500 different functions including fights off infection, neutralizing 
toxins, manufacturing proteins and hormones, controlling blood sugar and helping to clot the 
blood. 
 The liver is the largest internal and most metabolically complex organ in humans. 
 The liver is the only organ that can regenerate itself thus making it possible for one 
person to donate part of their liver to another person. When a portion of the liver is transplanted, 
the donor's liver will regenerate back to its original size while the transplanted portion will grow 
to the appropriate size for the recipient. 
 The liver has an enormous task of maintaining the body„s metabolic homeostasis. This 
includes, the processing of dietary amino acids, carbohydrates, lipids, and vitamins; synthesis of 
serum proteins; and detoxification and excretion into bile of endogenous waste products and 
pollutant xenobiotics. Hepatic disorders have far reaching consequences, given the critical 
dependence of other organs on the metabolic functions of the liver. Liver injury and its 
manifestations tend to follow characteristic patterns. In some instances, the diseased process is 
primary to the liver. In others, the hepatic involvement is secondary, often to some of the most  
Common diseases in humans, such as cardiac decompensation, alcoholism and extra hepatic 
infections with progression of diffused disease or strategic disruption of  circulation or bile 
flow.  
1) Inflammation: Injury to hepatocytes associated with an influx of acute or chronic 
inflammatory cells into the liver is termed hepatitis. Attack of viable antigen- expressing liver 
cells by sensitized T-cells is a common cause of liver damage. Inflammation may be limited to 
portal tract or may spill over into the parenchyma.  
  E.g., viral hepatitis due to hepatitis A virus (HAV), HBV, HCV, HDV and HEV.  
 
 
Fig 2: Liver anatomy 
2) Degeneration: The hepatocytes get damaged due to toxic or immunological insult and show 
an edematous appearance. Degeneration can also be in the form of stetosis, where in there is 
accumulation of fat droplets within the hepatocytes. e.g., hepatic degeneration can be due to 
genetic diseases or exogenous substance such as alcohol.  
3) Cell death:  
 Cell death which is toxic or immunologically mediated occurs via apoptosis wherein the 
hepatocytes become shrunken, pyknotic, and intensely eosinophilic. Alternatively, hepatocytes 
may also undergo lytic necrosis (osmotically swell and rupture). The other types are centrilobular 
necrosis, bridging necrosis, submassive necrosis and massive necrosis.  
4) Fibrosis: 
 Fibrotic tissue is formed in response to inflammation or direct toxic insult to the liver. 
Deposition of collagen has lasting consequences on hepatic pattern of blood flow and perfusion 
of heapatocytes. Initially fibrosis may develop within or   around portal tracts or the central 
vein or may be deposited directly with in the sinusoids. Progressively, these fibrous strands link 
regions of the liver (portal-to-portal, portal-to-central, central-to-central),a process called 
bridging fibrosis. Fibrosis is generally considered as an irreversible consequence of hepatic 
damage.  
5) Cirrhosis: 
 Cirrhosis with continuing fibrosis and parenchyma injury, the liver is subdivided into 
nodules of degenerating hepatocytes surrounded by scar tissue, termed cirrhosis and is an end 
stage form of liver.  
 
Figure 3:Cirrhosis 
  The clinical consequences of liver diseases are hepatic dysfunction in the form of 
jaundice, hypoalbuminemia, hyperammonemia, hyperglycemia, fector hepatitis, palmar 
erythema, spider angiomas, hypogonadism, gynecomastia, weight loss, muscle wasting, and 
portal hypertension from cirrhosis. If these are not treated promptly, they will lead to life 
threatening complications like hepatic failure in the form of hepatic encephalopathy, 
hepatorenal-syndrome; or portal hypertension from cirrhosis, Malignancy with chronic disease 
and hepatocellular carcinoma 
 
2.5. Causes of liver disease: 
Liver disease can be caused by a variety of factors. Causes include:  
• Congenital birth defects, or abnormalities of the liver present at birth  
• Metabolic disorders, or defects in basic body processes  
• Viral or bacterial infections  
• Alcohol or poisoning by toxins  
• Certain medications that is toxic to the liver  
• Nutritional deficiencies  
• Trauma, or injury 
2.6. Liver functions: 
 The liver is a metabolically active organ responsible for many vital life functions. The 
primary functions of the liver are include bile production, metabolic functions, blood 
detoxification or purification and storage of vitamins and minerals 
The liver is thought to be responsible for up to 500 separate functions,usually in combination 
with other systems and organs  
 The liver forms part of the gastrointestinal system, which is responsible for breaking 
down food into smaller parts that can be used by cells.  The liver is located in the abdomen, 
below the ribcage. It is a large organ with many different functions, including: (Vander AJ; 
2004) 
• Production and secretion of bile and bile salts to help digestion and absorption. 
• Production of insulin-like growth factor (IGF-I). 
• Production of clotting factors. 
• Release of glucose into the blood to provide energy for cells. 
• Production of urea, a waste product. 
• Cholesterol production. 
 
 Behind the liver there‟s a small organ called the gallbladder, which function‟s to store 
bile produced by the liver and empty it into the small intestine to aid digestion and 
absorption.(Starr C;2008) 
 Bile or gall is a dark green to yellowish brown fluid, produced by the liver of most 
vertebrates that helps the digestion of lipids in the small intestine. In humans, bile is produced by 
the liver (liver bile), and stored and concentrated in the gallbladder (gallbladder bile). Volume 
secreted per day is about 600-1000 ml and ph is around 8 and also bile helps in the 
emulsification of fats. 
 
 Bile salts are derived from bile acids. These are synthesized in the liver from cholesterol 
by hepatocytes. The two important bile acids are cholic acid and chenodeoxy cholic acid which 
are produced in the liver from cholesterol. 
Blood purification 
 Blood from the stomach and intestines is filtered by the liver. To prevent contaminants 
from circulating in the bloodstream, the liver removes a plethora of toxic waste from our 
circulation, such as bacteria, antigens, imperfect or no-longer functioning blood cells e.g. 
damaged leukocytes and erythrocytes 
 
Metabolic function 
1) Carbohydrate metabolism 
Maintenance of normal blood glucose level: 
      When blood glucose is low the liver breaks stored glycogen down into glucose and release 
into the blood stream. 
      When blood glucose is high the liver converts glucose to glycogen and triglycerides (for 
storage). 
2) Protein Metabolism 
The most critical aspects of protein metabolism that occur in the liver are: 
• Deamination and transamination of amino acids, followed by conversion of the non-
nitrogenous part of those molecules to glucose or lipids. Several of the enzymes used in 
these pathways (for example, alanine and aspartate aminotransferases) are commonly 
assayed in serum to assess liver damage. 
• Removal of ammonia from the body by synthesis of urea. Ammonia is very toxic and if 
not rapidly and efficiently removed from the circulation, will result in central nervous 
system disease. A frequent cause of such hepatic encephalopathy in dogs and cats are 
malformations of the blood supply to the liver called portosystemic shunts. 
• Synthesis of non-essential amino acids. 
• Hepatocytes are responsible for synthesis of most of the plasma proteins. Albumin, the 
major plasma protein, is synthesized almost exclusively by the liver. Also, the liver 
synthesizes many of the clotting factors necessary for blood coagulation. 
3) Lipid metabolism 
  The liver is the center of lipid metabolism. It manufactures nearly 80% of the cholesterol 
synthesized in the body from acetyl-CoA via a pathway that connects metabolism of 
carbohydrates with that of lipids. Moreover, the liver can synthesize, store, and export 
triglycerides. The liver is also the site of keto acid production via the pathway of fatty acid 
oxidation that connects lipid catabolism with activity of the tricarboxylic acid cycle.  
  In the process of controlling the body's level of cholesterol and triglycerides, the liver 
assembles, secretes, and takes up various lipoprotein particles. Some of these particles (very low-
density lipoproteins [VLDL]) serve to distribute lipid to adipose tissue for storage as fat or to 
other tissues for immediate use. In the course of these functions, the structure of VLDL particles 
is modified by loss of lipid and protein components. The resulting low-density lipoprotein (LDL) 
particles are then returned to the liver by virtue of their affinity for a specific receptor, the LDL 
receptor, found on the surface of various cells of the body, including hepatocytes. Other 
lipoprotein particles (high-density lipoproteins [HDL]) are synthesized and secreted from the 
liver. They scavenge excess cholesterol and triglycerides from other tissues and from the 
bloodstream, returning them to the liver where they are excreted. Thus, secretion  of HDL and 
removal of LDL are both mechanisms by which cholesterol in excess of that needed by various 
tissues is removed from the circulation  
 
4) Hematological functions (Haematopoeisis and coagulation)  
  1. Production of fibrinogen, prothrombin, heparin, and other clotting factors VII, VIII,  
       IC and C.  
   2. Destruction of erythrocytes. (at the end of their respective life span) 
  
5) Circulatory function  
  1. Transfer of blood from portal to systemic circulation  
  2. Blood storage (regulation of blood volume)  
 
 6) Detoxification and protective functions  
  1. Kupffer cells remove foreign bodies from blood (phagocytosis).  
  2. Detoxification by conjugation, methylation, oxidation and reduction.  
  3. Removal of ammonia.  
Removal of ammonia 
 When exposed to harmful substances, toxins may enter in our body like pesticides; 
however it results from normal digestion. 
 For example, when our body digests protein, ammonia is released and your liver converts 
it into the less toxic substance called urea that is eliminated through urine. If any wastage it can 
either carried by bile into your small intestines or carried by the blood to your kidneys. 
2.7. A symptom of liver diseases includes: 
Symptoms may begin slowly and slowly get worse. They may also begin suddenly and be severe 
from the start. (Nevah MI et al; 2016) 
Early symptoms may be mild and include: 
• Breath with a musty or sweet odor 
• Change in sleep patterns 
• Changes in thinking 
• Confusion that is mild 
• Forgetfulness 
• Mental fogginess 
• Personality or mood changes 
• Poor concentration 
• Poor judgment 
• Worsening of handwriting or loss of other small hand movements 
 
More severe symptoms may include: 
 Abnormal movements or shaking of hands or arms 
 Agitation, excitement, or seizures (occur rarely) 
 Disorientation 
 Drowsiness or confusion 
 Strange behavior or severe personality changes 
 Slurred speech 
 Slowed or sluggish movement 
 People with hepatic encephalopathy can become unconscious, unresponsive, and possibly 
enter a coma. 
 A rare but severe form of the liver infection called acute fulminant hepatitis causes liver 
failure. Symptoms of liver failure include:  
 An enlarged and tender liver  
 Enlarged spleen  
 Susceptibility to bleeding  
 Encephalopathy, which is a disorder that affects how the brain functions  
 Changes in mental status or level of consciousness  
 Ascites, which is an accumulation of fluid inside the abdomen  
 Edema or swelling under the skin  
 Aplastic anemia, a condition in which the bone marrow cannot make blood cells 
2.8. Diagnosis 
Many further tests may also be used to support the diagnosis. These include blood tests, such as:  
 Liver function tests, which are blood tests that check a wide variety of liver enzymes and 
byproducts  
 A complete blood count (CBC), which looks at the type and number of blood cells in the 
body  
 Abdominal X-rays  
 Ultrasounds, to show size of abdominal organs and the presence of masses  
 An upper GI study, which can detect abnormalities in the esophagus caused by liver 
disease  
 Liver scans with radio tagged substances to show changes in the liver structure  
 ERCP, or endoscopic retrograde cholangiopancreatography. A thin tube called an 
endoscope is used to view various structures in and around the liver.  
 Abdominal CT scan or abdominal MRI, which provide more information about the liver 
structure and function  
 Fig No:4 Dignosis 
Diagnosis of Drug-Related Hepatotoxicity. 
 There is no single test, including liver biopsy that can be used to diagnose drug-related 
Hepatotoxicity. Other causes of liver injury must first be considered with the use of a 
combination of serologic tests, imaging studies, and clues from the patient‟s history. CT denotes 
computed tomography, MRI magnetic resonance imaging, MRCP magnetic resonance 
cholangiopancreatography, ERCP endoscopic retro grade cholangiopancreatography, AST 
aspartate aminotransferase, ALT alanine aminotransferase, TIBC totaliron-binding capacity, and 
A1AT alpha1-antitrypsin 
2.9. Liver disease 
 One way to classify liver disease is by their duration. A chronic disorder lasts for more 
than 6 months; a sub acute disorder lasts for 3 to 6 months, while an acute disorder occurs over a 
period less than 3 months. A very severe disorder that leads to liver failure within 6 weeks is 
termed fluminant. There are more than 100 different types of liver disease, which together affect 
at least 2 million people in the UK. 
 Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C 
Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease, 
hepatic encephalopathy, and cirrhosis. 
Liver cancer 
 Inherited diseases, such as hemochromatosis and Wilson disease. 
Liver injury is defined as an alanine aminotransferase (ALT) level of more than three times the 
upper limit of the normal range, an alkaline phosphatase (ALP) level of more than twice the 
upper limit of normal, or a total bilirubin (TBL) level of more than twice the upper limit of 
normal if associated with any elevation of the alanine aminotransferase or alkaline phosphatase 
level. Liver injury is further characterized as Hepatocellular when there is a predominant initial 
elevation of the alanine aminotransferase level or as cholestatic when there is a predominant 
initial elevation of the alkaline phosphatase level; a mixed pattern comprises elevations of both 
the alanine aminotransferase and alkaline phosphatase levels. Recognizing the pattern of liver 
injury helps to categorize it, since drugs tend to create injury predominantly in one or another 
pattern. The injury patterns are not mutually exclusive, and a mixed pattern of injury may occur 
in many instances of drug-related hepatotoxicity. HAART denotes highly active antiretroviral 
therapy, and NSAIDs nonsteroidal antiinflammatory drugs.( Navarro VJ et al;2007) 
 
 
 
 
 
2.9.1. Alcoholic liver disease: 
 It is the major cause of liver disease in Western countries. Although alcoholic 
steatosis (fatty liver), alcoholic hepatitis, alcoholic cirrhosis will develop in any individual who 
consumes a large quantity of alcoholic over a long period of time. 
Fat can accumulate in the liver in excessive amounts, thus resulting in a fatty liver; the 
accumulation of fat in alcoholic steatosis may also be accompanied by a progressive 
inflammation of the liver (hepatitis), called steatohepatitis. This more severe condition may be 
termed either alcoholic steatohepatitis  
2.9.2. Non-Alcoholic fatty liver disease: 
 Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs 
when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol 
use. NAFLD has a number of causes, including being overweight, diabetes, high blood fats, 
and high blood pressure. 
a) Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD. 
Long term effects of the disease: 
Long- term effects depend on the type of liver disease present. For example, chronic hepatitis 
can lead to:  
 Cirrhosis of the liver  
 Liver failure  
 Illnesses in other parts of the body, such as kidney damage or low blood counts 
Other long-term effects of liver disease may include:  
 Gastrointestinal bleeding. This includes bleeding esophageal varices, which are 
 abnormally enlarged veins in the esophagus and/or the stomach.  
 Encephalopathy, which is deteriorating brain function that may progress to a 
 coma  
 Peptic ulcers, which erode the stomach lining  
 Liver cancer 
b) Cirrhosis 
 Cirrhosis is most commonly caused by alcohol, hepatitis B, hepatitis C, and non-
alcoholic fatty liver disease. Cirrhosis is a condition in which the liver does not function 
properly due to long-term damage. This damage is characterized by the replacement of normal 
liver tissue by scar tissue. Typically, the disease develops slowly over months or years. Early on, 
there are often no symptoms. As the disease worsens, a person may become tired, weak, itchy, 
have swelling in the lower legs, develop yellow skin, bruise easily, have fluid buildup in the 
abdomen, or develop spider-like blood vessels on the skin. Cirrhosis is the end result of chronic 
liver damage. 
Alcoholic cirrhosis, like all forms of cirrhosis, is often life threatening. The disease is 
characterized by regenerative nodules of hepatic tissue completely surrounded by fibrous scar 
tissue. The scar tissue grows faster than liver cells can regenerate, and the growing network of 
scar tissue inhibits blood flows. Once cirrhosis develops, the risk of liver cancer elevates 
substantially, even if the patient abstains from drinking for several years. 
c) Hepatic encephalopathy 
 Hepatic encephalitic can occur in those with acute or chronic liver disease. Episodes can 
be triggered by infections, Gastro intestinal bleeding, constipation, electrolyte problems, or 
certain medications. This problem may occur suddenly or develop slowly over time. 
 Loss of brain function occurs when the liver is unable to remove toxins from the blood.it 
is neuropsychiatric syndrome associated with acute liver failure, chronic parenchymal liver 
disease or portal systemic shunting. The spectrum of symptoms may vary from subtle mental 
changes with recurrent disturbances in consciousness, impairment of intellectual function, 
neuromuscular dysfunction, elevated arterial blood ammonia concentration (Chu et al., 2001). 
 
Hepatitis 
 Hepatitis is a liver disease characterize by swelling and inadequate functioning of liver. 
Hepatitis may be acute or chronic. In severe conditions, it may lead to liver failure and death.  
 
Causes and Types: 
Hepatitis is caused by viruses, bacteria poisons, autoimmune disease drug abuse, alcohol, some 
therapeutic drugs and inheritance from mother during parturition. Viral hepatitis is of five types 
namely, hepatitis A, B, C, D and E.  
  Hepatitis A and E are caused mostly by intake of water and food contaminated with 
hepatitis virus. Generally these two types of hepatitis are not life threatening.  
  Hepatitis B, C and D are caused by sharing needles with infected person, accidental prick 
by infected needle, having unprotected sex with infected person, inheritance from mother during 
parturition and blood transfusion from infected donors.  
 
Figure 5 : Hepatitis 
 These three forms of hepatitis are serious diseases when compared to hepatitis A and E. 
Among these, hepatitis B is more common and considered more serious because it may lead to 
cirrhosis and cancer of liver 
Alcoholic hepatitis is inflammation of the liver, and can exist as either acute or chronic 
conditions. Symptoms can vary greatly, from asymptomatic to severe fever, nausea, and 
abdominal pain. Acute hepatitis can often cause death, and the chronic form often leads to 
cirrhosis. On the bright side, alcoholic hepatitis is also potentially reversible, if recovery occurs 
and the patient abstains from drinking. 
Jaundice (Sembulingam K; 2004)
 
 This is the yellow pigmentation of the skin, mucous membrane and deeper tissues due to 
increased bilirubin level in blood. The normal serum bilirubin level is 0.5 to 1.5 mg%. When this 
serum bilirubin level exceeds 2 mg %, jaundice occurs.  
Types and causes of Jaundice  
 Jaundice is classified into three type„s namely haemolytic jaundice, hepatocellular 
jaundice, and obstructive jaundice.  
a) Hemolytic Jaundice  
  Hemolytic jaundice is also called prehepatic jaundice. During this, the excretory function 
of liver is normal. But, there is excessive destruction of red blood cells and thus the bilirubin 
level in blood is increased the liver cells cannot excrete much bilirubin rapidly. So, it 
accumulates in the blood resulting in jaundice. In this type of jaundice the free bilirubin level 
increases in blood. Increased in formation of urobilinogen in resulting in the excretion of more 
amount of urobilinogenin urine. Any condition that causes hemolytic anemia can lead to 
hemolytic jaundice.  
It represents the inability of the liver to excrete bilirubin due to various defects in the liver like 
a) Criggler Najjar Disease 
b) Dubin-Johnson Syndrome 
c) Gilbert's disease. 
d) Neonatal Physiological Jaundice. 
 
b) Hepatocellular Jaundice  
 The jaundice due to the damage of liver cells is called Hepatocellular or hepatic jaundice. 
It is also called hepatic cholestatic jaundice. Here, bilirubin is conjugated. But the conjugated 
bilirubin cannot be excreted. So, it returns to the blood. The damage of liver cells occurs because 
of toxic substances (toxic jaundice) or by infection (infective jaundice). Commonly liver is 
affected by virus resulting in hepatitis.  
c) Obstructive Jaundice  
 This is otherwise called extra hepatic cholestatic jaundice or post hepatic jaundice. It is 
due to the obstruction of bile flow at any level of biliary system. The bile cannot be poured into 
small intestine and bile salts and bile pigments enter the circulation. In this, blood contains more 
conjugated bilirubin. 
This is caused due to obstruction of biliary tract, ductal occlusions by stones or 
compression by neoplastic diseases. There is an increase in the levels of conjugated bilirubin in 
post hepatic jaundice (Guyton and Hall, 2002) 
Hemochromatosis is a condition in which too much iron is contained in the body. It is the most 
common genetic disease. Chronic hemochromatosis can lead to cirrhosis, cancer, impotence and 
heart problems. Iron damages the body through its promotion of oxidation, increasing the level 
of free radicals in the body. Harmful levels of iron can be accumulated in body simply by eating 
too of the wrong foods and supplements. The human body uses approximately I to 2 milligrams 
of iron daily. However, the average diet contains between 10 and 20 milligrams of iron. In 
hemochromatosis, the body cannot absorb iron as effectively, and also cannot detect when iron 
levels are too high. This excess iron is then absorbed into the body's organs, particularly the 
liver. Hemochromatosis is treated by lowering the level of iron in the body. The most common 
method is via phlebotomies. A phlebotomy is purposefully removing blood from the body. Diet 
is also very important to patients with hemochromatosis. Iron needs to be kept to a minimum, as 
well as alcohol and medications that may do further damage to the liver. 
Gallstones 
 Cholesterol secreted by liver into the bile, may precipitate in the gall bladder to produce 
gallstones. Occasionally a gallstone may pass out of the gall bladder and enter the cystic duct, 
blocking the release of bile. Such a condition interferes with normal digestion, and often 
cholecystectomy is carried out (Guyton and Hall, 2002). 
1.4.11. Gilbert's Syndrome 
 It is a fairly common, mild liver disorder. People with this disorder have a moderate, 
fluctuating increase in serum bilirubin, and further increase in bilirubin may produce jaundice 
(Crawford, 2004). 
 2.9.3. Inborn Errors of Metabolism 
Antitrypsin Deficiency 
 It is an inherited condition. In this condition, the alpha antitrypsin, which is produced by 
the body, is abnormal with no protective activity and is not released in sufficient amount from 
the liver. 
Wilson Disease 
 Wilson disease is a relatively rare hereditary condition in which excessive amounts of 
copper accumulate in the body including liver which leads to cirrhosis. 
Hemochromatosis 
 Hereditary hemochromatosis refers to an HLA- linked autosomal recessive disease 
characterized by excessive accumulation of body iron, most of which is deposited in liver 
(Crawford, 2004). 
Liver diseases most likely to be seen in children include:  
Galactosemia: an inherited disease in which the body can not tolerate certain sugars in milk. 
These sugars can build up, causing serious damage to the liver and other organs of the body.  
Alagille's syndrome: a condition in which the bile ducts narrow and deteriorate, especially 
during the first year of life  
Alpha 1- antitrypsin deficiency: a genetic liver disease in children that can lead to hepatitis and 
cirrhosis of the liver  
Neonatal hepatitis: which is hepatitis that occurs in a newborn during the first few months of 
life  
Tyrosinemia: a disorder that causes serious problems with liver metabolism  
Hemorrhagic telangiectasia: a condition in which thin blood vessels allow frequent and easy 
bleeding of the skin and digestive tract  
Reye's syndrome: a condition that causes a buildup of fat in the liver. This condition has been 
linked in some cases to use of aspirin, especially in conjunction with chickenpox, influenza, or 
other illnesses with fever.  
Wilson's disease: an inherited condition that causes a buildup of the mineral copper in the liver  
Tthalassemia: a group of hereditary anemias, or low red blood cell counts  
Biliary atresia: a condition in which the bile ducts extending from the liver to the intestine are 
too small in diameter or are missing  
Chronic active hepatitis: an inflammation of the liver that causes severe scarring and 
interference with liver function  
Like other parts of your body, cancer can affect the liver. You could also inherit a liver disease 
such as hemochromatosis.  
2.9.4.Pediatric liver diseases 
Reye Syndrome 
 Reye syndrome is a rare disease characterized by fatty infiltration and encephalopathy. It 
primarily affects children younger than 4 years. Laboratory findings include elevated blood 
ammonia, serum transaminases and prolonged prothrombin time. 
  
 
 
Neonatal Hepatitis 
 It is an inflammation of the liver that occurs in early infancy, usually one to two months 
after birth. Viruses, which can cause neonatal hepatitis in infants, include cytomegalovirus, 
rubella (measles), and hepatitis A, B and C (Crawford, 2004). 
Hepatotoxicity 
 A large variety of chemical compounds have identified as hepatotoxins. Liver injury 
induced by chemicals has been recognized as a toxicological problem for more than 100 years. 
"Liver injury is not a single entity; the lesion observed depends only on the chemical agents 
involved, but also on the period of exposure. The vulnerability of the liver to chemically induced 
damage is a function of 
 a) Its anatomical proximity to the blood supply from digestive tract 
 b) Its ability to concentrate and biotransform foreign chemicals. 
 c) Its role in the excretion of xenobiotics or their metabolites in bile (Plaa and 
     Charbonneau, 1994). 
2.9.5. Liver necrosis:  
Liver necrosis is divided into 3 types.  
 
 
Fig No 5: Liver cancer 
 Diffuse necrosis:  
 When there is extensive and diffuse necrosis of the liver involving all the cells in group 
of lobules it is termed as diffuse or submassive to massive necrosis[11]. Most commonly caused 
by the viral hepatitis and drug toxicity.  
Zonal necrosis:  
It is a necrosis of hepatocytes in 3 different zones of the hepatic lobules. Accordingly it is 
of 3 types:  
i. Centrilobular necrosis is the commonest type involving hepatocytes in zone-3. 
Centrilobular necrosis is the characteristic feature of ischemic injury such as in shock and 
CHF.  
ii. Midzonal necrosis is uncommon and involves zone-2 of hepatic lobule. This pattern of 
necrosis is seen in yellow fever and viral hepatitis.  
iii. Periportal necrosis is seen in zone-1 involving the parenchyma closest to the arterial and 
portal blood supply. It is almost vulnerable to the effects of circulating hepatotoxins.  
Focal necrosis:  
 This form of necrosis involves small groups of hepatocytes irregularly distributed in the 
hepatic lobule. Focal necrosis is generally caused by microbiological infections. 
2.10. Risk Factor of hepatotoxicity 
 Several conditions are Responsible for development of Hepatotoxicity. Liver injury 
involve certain risk factors that can be genetic, non genetic or environmental [41]. Adverse effect 
of drug or metabolites (like, antiretroviral drug nad alcholol) and certain health condition such as 
age, sex, disease (HIV or diabetes) are coupled with each other [42]. Some Resent research on 
hepatic injury and various disease condition Show increased hepatotoxicity among HIV, Diabetic 
or Tuberculosis patient 
 Fig No6:Risk factors 
Race: Some drugs appear to have different toxicities based on race. For example, blacks and 
Hispanics may be more susceptible to isoniazid (INH) toxicity. The rate of metabolism is under 
the control of P-450 enzymes and can vary from individual to individual.  
Age: Apart from accidental exposure, hepatic drug reactions are rare in children. Elderly persons 
are at volume. In addition, poor diet, infections, and multiple hospitalizations are important 
reasons for drug-induced hepatotoxicity.  
Sex: Although the reasons are unknown, hepatic drug reactions are more common in females.  
Alcohol Ingestion: Alcoholic persons are susceptible to drug toxicity because alcohol induces 
liver injury and cirrhotic changes that alter drug metabolism. Alcohol causes depletion of 
glutathione (hepatoprotective) stores that make the person more susceptible to toxicity by drugs.  
Liver disease: In general, patients with chronic liver disease are not uniformly at increased risk 
of hepatic injury. Although the total cytochrome P-450 is reduced, some may be affected more 
than others. The modification of doses in persons with liver disease should be based on the 
knowledge of the specific enzyme involved in the metabolism. Patients with HIV infection who 
are co-infected with hepatitis B or C virus are at increased risk for hepatotoxic effects when 
treated with antiretroviral therapy. Similarly, patients with cirrhosis are at increased risk of 
decompensation by toxic drugs. 
Other comorbidities: Persons with AIDS, persons who are malnourished, and persons who are 
fasting may be susceptible to drug reactions because of low glutathione stores.  
Drug formulation: Long-acting drugs may cause more injury than shorter-acting drugs. 
Host factors that may enhance susceptibility to drugs, possibly inducing liver disease  
a) Female - Halothane, nitrofurantoin, sulindac  
b) Male - Amoxicillin-clavulanic acid (Augmentin)  
c) Old age - Acetaminophen, halothane, INH, amoxicillin-clavulanic acid  
d) Young age - Salicylates, valproic acid  
e) Fasting or malnutrition - Acetaminophen  
f) Large body mass index/obesity - Halothane  
g) Diabetes mellitus - Methotrexate, niacin  
h) Renal failure - Tetracycline, allopurinol  
i) AIDS - Dapsone, trimethoprim-sulfamethoxazole  
j) Hepatitis C - Ibuprofen, ritonavir, flutamide  
k) Preexisting liver disease - Niacin, tetracycline, methotrexate  
Genetic factor 
 Idiosyncratic drug-induced liver injury (DILI) significantly associate with certain genetic 
traits and Genetic studies conducted till now abundantly have been hypothesis-driven only, 
Which involved a candidate compound–candidate gene approach . According to Jae Woo-kwon 
et al genetic variations in thioredoxin reductase 1 gene (TXNRD1) leads toward development of 
DILI.(Aggarwal BB et al;2007)  Variation in activity of drug metabolizing enzyme, (such 
asCYPS3A, CYP2C9, CYP2C19) which require for drug metabolism lead to pathogenesis of 
idiosyncratic DILI [229]. Polymorphism of bioactivities pathway through CYP450 enzymes, 
detoxification reactions and excretion/transport reaction together with immunological factors 
(HLA class II antigen, cytokines ) are major genetic factor that can effect Hepatotoxicity(Wilke 
RA et al;2007) 
 
Non Genetic Factor 
 Environmental factors like Age, gender, Drug dose, alcohol abuse and some disease 
condition like HIV, and TB also associate with Hepatotoxicity. For specific medication age is 
important risk factor for Hepatotoxicity such as use of aspirin in younger age increase risk to 
liver injury [50, 51]. Large scale study on age factor in US patient has been done, shows between 
25-34 age Hepatotoxicity is 4.4 par 1000 patients where as it increase vigorously to 20.83 per 
1000 patient at the age of 50 or older (Lucena MI et al;2006)  
 Women and men have different susceptibility for drug induced hepatotoxicity. For 
example according to Hyman and Zimmermanin in 1978 women are more susceptible for drugs 
like isoniazid, nitrofurantoin, chlorpromazine etc where as men are mostly affected azathioperine 
induced hepatotoxicity [53]. Other factor like obesity (increased expression of CYP2E1 
Associated condition), also responsible for liver injury [228] acute and chronic alcohol 
consumption associated hepatotoxicity has been reported in various experiment. Some disease 
condition like HIV tuberculosis, Hepatitis B and C associate disease always increase of liver 
injury.(Ekstedt M et al;2007)  
 
2.11. Hepatotoxicity 
Many xenobiotics like chemicals, Drugs, house hold things, herbs and environmental chemicals 
have been known to induce hepatotoxicity. Most important for xenobiotic-induced hepatic 
damage, the centrilobular (zone three) hepatocytes are the primary sites of cytochrome P450 
enzyme activity, which frequently makes them most susceptible to xenobiotic-induced liver 
injury. Carbontetrachloride (CCl4), N-nitrosodiethylamine (NDEA), Acetylaminofluorene (2-
AAF), Galactosamine, d-Galactosamine /Lipopolysachharide (GalN/LPS), Thioacetamide, 
antitubercular drugs, paracetamol, arsenic etc. are used to induce experimental hepatotoxicity in 
laboratory animals. Some list of chemicals is follow that are responsible for 
hepatotoxicity(Zimmerman HJ;1978) Industrial chemical: CCl4, Trtra chloroethane Di 
phenyleoxide Chloroform, Ethylene dichloride, Arsenic, Antimony, Copper, Hydrezines House 
hold thing: Antifreeze Dry cleaning fluids Glue, Stamping Ink Paint Products, Polishes, Paint 
remover, Wax Pesticides: Orgenochloride, insecticide Herbicide, fungicide Thallium, warfarin 
Copper salt DDT Pollutant chemical in food and water: Polychloridated Biphenyls 
Polybrominated biphenyls Chloroalkane Plant Extract: Pyrrolizidine alkaloids, Pennyroyal, Kava 
Kava, Broom corn, Bajiaolian, Margosa Oil, Jin Bu Huan, Chaparral Drugs: Paracetamol AAF 
AAP, APAP, Acetophenazine Maleate AmrinoneLactate, Azacitidine, Asparaginase, Blenoxane 
Anti Tuberculosis drug: Isoniazid, Rifampicin, Rifabutin Pyrazinamide Ethionamide, 
Prothionamide Para-aminosalicylic acids  
Hepatotoxicants: 
A) Producing zonal Hepatocellular alterations: 
Carbon tetrachloride 
Chloroform 
Phosphorus 
Tannic acid 
Ethionine 
Ethanol 
B) Producing bilary dysfunction 
Phenothiazine derivatives 
Antimicrobial agents 
Anabolic steroids 
Oral hypoglycemic 
C) Producing Hepatocellular necrosis 
 Iproniazid  
  MAO inhibitcn 
  Halothane 
2.11.1. Mechanisms of liver toxicity (Chun LJ et al;2009) 
 The pathophysiologic mechanisms of hepatotoxicity are still being explored and include 
both hepatocellular and extracellular mechanisms. The following are some of the mechanisms 
that have been described:  
 Disruption of the hepatocyte: Covalent binding of the drug to intracellular proteins can cause a 
decrease in ATP levels, leading to actin disruption. Disassembly of actin fibrils at the surface of 
the hepatocyte causes blebs and rupture of the membrane.  
 
Disruption of the transport proteins: Drugs that affect transport proteins at the canalicular 
membrane can interrupt bile flow. Loss of villous processes and  
interruption of transport pumps such as multidrug resistance–associated protein 3 prevent the 
excretion of bilirubin, causing cholestasis.  
Cytolytic T-cell activation: Covalent binding of a drug to the P-450 enzyme acts as an 
immunogen, activating T cells and cytokines and stimulating a multifaceted immune response. 
 Apoptosis of hepatocytes: Activation of the apoptotic pathways by the tumor necrosis factor-
alpha receptor of Fas may trigger the cascade of intercellular caspases, which results in 
programmed cell death.  
 
Mitochondrial disruption: Certain drugs inhibit mitochondrial function by a dual effect on both 
beta-oxidation energy production by inhibiting the synthesis of nicotinamide adenine 
dinucleotide and flavin adenine dinucleotide, resulting in decreased ATP production.  
 
Bile duct injury: Toxic metabolites excreted in bile may cause injury to the bile duct epithelium. 
 
 
2.11.2. Classification of hepatotoxins:  
Table 1. Classification of hepatotoxins 
Category of agent 
Mechanism 
 
Histological 
Lesion 
Examples 
 
1. Intrinsic toxicity  
a) Direct  
Membrane injury 
destruction of 
structural basis 
of cell 
metabolism  
Necrosis and / or 
steatosis  
CCl4, CHCl3, 
Phosphorus  
 Interference with Steatosis or Ethionine  
b) Indirect  
Cytotoxic  
specific 
metabolic 
pathway leads to 
structural injury  
necrosis  Thioacetamide  
Paracetamol  
Ethanol  
 
c) Cholestatic  
Intereference 
with bile 
excretory 
pathway leads to 
Cholestasis  
Bile duct injury  
Rifampicin  
Steroids  
 
2. Host idiosyncrasy  
 
      a) Hypersensitivity  
Drug allergy  
 
Necrosis or 
cholestasis  
Sulfonamides  
Halothane  
 
b) Metabolic abnormality  
 
Production of 
hepatotoxic 
metabolites  
Necrosis or 
cholestasis  
Isoniazid  
 
 
 
 
 
 
 
 
Direct hepatotoxins and their effects: 
Table 2. Direct hepatotoxins and its effects 
Name Morphological alterations 
Carbon tetrachloride  Decreases glycogen and protein levels and 
increases the content of lipid  
Carbon tetrachloride-ethanol  Severely depletes glycogen level and increases 
the protein and lipid content  
Thioacetamide  Decreases the glycogen and protein levels 
without effecting any significant change in 
lipid level  
Paracetamol  Decreases the liver glycogen and protein 
contents severely and elevates lipid level  
Galactosamine  Decreases the content of glycogen and protein 
with marked elevation in lipid profile  
Fulvine  Produces edema and congestion, damaging 
effect of the parenchyma  
Phalloidin  Damages plasma membrane of the hepatocytes, 
as well as their active filaments 
Ethyl alcohol  Causes hepatocyte degeneration, collagen 
deposition and necrosis  
Alfa toxins  Thymidine incorporation into DNA of 
regenerating liver, synthesis of RNA  
Lanthanum chloride  Elevates the level of lipid , protein, α- and β 
globulinsin liver and decreases albumin in 
serum  
 
 
 
 
 
 
 
 
Indirect hepatotoxins: 
Drug  Class of agent  
Methyl testosterone  Anabolic steroid  
Methimazole  Antithyroid  
Erythromycin estolate  Chemotherapeutic  
Norethynoderal with mestranol  Oral contraceptive  
Chlorpropamide  Oral contraceptive  
Chlorpromazine  Tranquilizer  
Tetracycline  Chemotherapeutic  
Valporic acid  Anticonvulsant  
Halothane  Anesthitic  
Phenytoin  Anticonvulsant  
Methyl dopa  Antihypertensive  
Isoniazid  Chemotherapeutic  
Chlorthiazide  Diuretic  
Oxyphenisatin  Laxative  
Paracetamol  Analgesic  
Phenylbutazone  Antiinflammatory  
Sulfonamides  Chemotherapeutic  
Allopurinol  Xanthine oxidase inhibitor  
Rifampicin  Antitubercular  
Mimosa pudica 
Polygala chinensis (polygalaceae)  
Teucriumchamaedrys (Labiatae)  
Anti inflammatory 
Sedative  
Atiobesity  
Piper methysticum (Piperaceae)  Antiaxiety, Antipsychotic  
Callilepsislaureola (Asteraceae)  Anthelmentic, Antitussive, Antiimpotence  
Symphytumofficinale (Boraginaceae)  Antigastrointestinal ailments  
Tussilagofarfara (Asteraceae)  Treatment of lung and gastric diseases  
Lycopodiumserratum (Lycopodiaceae)  Analgesic  
Tripterygiumwilfordii (Celasteraceae)  Male contraceptive  
Polygonummultiflorum (Polygonaceae) Treatment of prostate cancer and hair loss 
 
  
Alcohol induced toxicity:  
Chronic excessive use of alcohol 
 
  
                                                            Continues drinking 
  
  Fatty liver Liver Fibrosis 
 
  Continues                          
CURED Continues drinking episode  drinking 
                          
    Abstinence 
                       Alcoholic hepatitis              Liver cirrhosis 
 
 
 
 
                                              DEATH                           Hepatocellular carcinoma 
 
                                  
Fig : Schematic representation of Alcoholic liver diseases and progression process 
Alcohol is metabolized by liver. This process produces a number of potentially dangerous 
byproduct.  
Alcohol is converted to acetaldehyde by the enzyme Alcohol dehydrogenase (ADH).The formed 
acetaldehyde is highly toxic. Normally the enzyme Aldehyde dehydrogenase (ALDH) rapidly 
oxidizes acetaldehyde to acetate. Both these enzymes ADH and ALDH are also involved in 
metabolism of vitamin A.  
Apart from ADH, the enzyme CYP2E1 ( microsomal ethanol oxidizing system; MEOS) is also 
involved in metabolizing alcohol. MEOS plays a major role when blood ethanol levels are high. 
CYP2E1 produces a toxic byproduct N-acetyl-p-benzo-quinone imine (NAPQI) which is 
responsible for damaging the hepatic protein 
 
 
Fig No 8: Liver disease 
Paracetamol induced liver toxicity:  
Paracetamol is a non-steroidal anti-inflammatory drug which is available as OTC(over the 
counter) drug. The caution of this acetaminophen (Paracetamol) is its active metabolite is injury 
to liver (i.e) leads to liver damage 
 
Normal dose of the drug- 4000mg per day (Maximum) (Franciscus A;2012) 
2000-3000mg per day is mostly recommended.  
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The active metabolite of acetaminophen is N-acetyl p-benzoquinoneimine(NAPQI)This NAPQI 
is toxic to the liver cells. Mostly the 90% of acetaminophen is metabolized by glucuronide and 
sulfate conjucation and then excreted in the urine. 5-10% is metabolized by cytochrome P450, 
mainly by CYP2E1 which produces NAPQI. 
 
 
 
 
 
CCl4 induced toxicity: 
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Carbon tetrachloride has been widely used to study liver damage used by free radicals. CCl4 
toxicity is initiated by the bioactivation of CCl4 to CCl3 (tricloromethyl free radicals) by the 
enzymes CYP2E1, CYP2B1, CYP2B2, CYP3A chiefly by CYP2E1 (Pandit A et al) 
 
 
The formed CCl3 rapidly reacts with molecular oxygen to form CCl3O2 (peroxytricloromethyl 
free radicals). Both CCl3 and CCl3O2 are highly reactive, they covalently bind to 
macromolecules such as proteins, lipids and nucleic acids and react with polyunsaturated fatty 
acids and form a series of self-propagating chain reactions known as “propagation of lipid 
peroxidation 
 
2.12. Prevention:  
Some, but not all, liver diseases can be prevented. For example, hepatitis A and hepatitis B can 
be prevented with vaccines.  
Other ways to decrease the risk of infectious liver disease include: 
• Practicing good hygiene, such as washing hands well after using the restroom or changing 
diapers. 
• Avoiding drinking or using tap water when traveling internationally. 
• Avoiding illegal drug use, especially sharing injection equipment.  
• Practicing safest sex. Practicing safer sex provides less protection.  
• Avoiding the sharing of personal hygiene items, such as razors or nail clippers.  
• Avoiding toxic substances and excess alcohol consumption. 
• Using medications only as directed.  
• Using caution around industrial chemicals.  
• Eating a well balanced diet following the food guide pyramid.  
• Getting an injection of immune globulin after exposure to hepatitis A.  
• Using recommended safety precautions in healthcare and day care work. 
Animal Models in Liver Diseases 
By recent advances in science and increasing knowledge of the liver pathology diseases various 
animal models of liver diseases has come forth, 
The following table shows various hepatotoxicants induce various diseases. 
TABLE 3 
Agent Type of Liver Disease 
4-nitroquinolone- I-
oxide 
Cancer by oxidative stress (Srinivasan et al) 
Alfatoxin B Liver cancer (Mathur et.al., 1992). 
Allylalcohol  Focal liver necrosis (Vogel, 2002). 
Ant tubercular drugs 
in combination such 
as ionized, rifampin 
and pyriznamide 
Drug induced hepatotoxicity to produce degeneration, 
necrosis and fibrosis(Kale al., 2003). 
Carbontetrachloride-
CC14 Centrilobular necrosis. Catty live/ Oiid (sane, 2002) 
Chicken calvaria Fibrosis (Vogel , 2002) 
Concanavalin A 
Autoimmune, viral and alcohol hepatitis (Zhao et al., 
2004) 
D-L-Galactosamine-
GalN Hepatitis (Vimal and Devaki, 2004) 
Dimethyl hydrazine Cancer by oxidative stress (Anilakumar et al., 2004) 
Dimethylnitrosamine 
Necrosis, fibrosis, hepatopathy and nodul regeneration 
and cancer in liver (Lee et al;2004) 
Doxorubicin Oxidant hepatotoxicant (Mostafa et al., 2000) 
Ethyl alcohol 
Fibrosis, hepatitis, cirrhosis and fatty liver (Bhandari et 
al;2003) 
Hamster mAb (J02) 
against mouse Fas 
antigen  Fulminant liver hepatitis (Rodriguez et al;1996) 
Hepatic ischemic 
reperfusion 
Oxidative stress, post ischemic injury hepatitis (Eum and 
Lee, 2004) 
Inhibiting protein 
hydroxylation* Fibrosis (Vogel, 2002) 
Lectin Fibrosis (Davidson, 2003) 
Paracetamol Drug induced hepatitis, necrosis (Asha et 2004) 
Lipopolysaccharide 
(LPS)  Liver sepsis ( Cho et al., 2003) 
siRNA (small 
inhibitory RNA) Autoimmune liver disorders (Davidson, 200 
Thioacetamide-TAA Cirrhosis, fibrosis (Wardi et al., 2001) 
 
*4 hydroxyproline confirms stability of collegenase protein liver and inhibiting p hydroxylation 
is possible target for the therapeutic antifibrotic agent could be evaluated (Vogel, 2002) 
 
. 
2. FREE RADICALS AND THEIR SCAVENGERS 
 
The ability to utilize oxygen has provided humans with the benefit of metabolizing fats, proteins, 
and carbohydrates for energy; however, it does not come without cost. Oxygen is a highly 
reactive atom that is capable of becoming part of potentially damaging molecules commonly 
called free radical or reactive oxygen species (ROS). About 5% or more of the inhaled 02 is 
converted to ROS such as O2-, H202 and OH by univalent reduction of O2 Thus cells under 
aerobic condition are always threatened with the insult of ROS, which however are efficiently 
taken care of by the highly powerful antioxidant systems of the cell without any untoward effect. 
When the balance between ROS production and antioxidant defence is lost, 'oxidative stress' 
results which through a series of events deregulates the cellular functions leading to various 
pathological condition 
Damage to cells caused by free radicals is believed to play a central role in various human 
disorders like rheumatoid arthritis, hemorrhagic shock. Cardiovascular disease, 
Fibrosis. Metabolic disorders, neurodegenerative disease, gastrointestinal ulcerogenosis and 
AIDS, Some specific examples of ROS mediated disease are Alzheimer's disease, Parkinson's 
disease, oxidative modification of low-density lipoprotein in atherosclerosis, cancer, Down's 
syndrome, and ischemic reperfusion injury in different tissues including heart, brain, kidney, 
liver, and gastrointestinal tract. Among these, role of ROS in atherosclerosis and ischemic injury 
in heart and brain studied extensively. (Bandyopadhyay U; 1999) 
The involvement of free radical reactions in the pathogenesis of liver injury has investigated for 
many years. Increasing evidence of free radical involvement reported for chronic ethanolic 
intoxication and iron overload, but the most striking proof Of a role of free radical chain 
reactions namely lipid peroxidation in the acute lethal damage o the hepatocyte has been 
obtained so far in ischemic hepatitis. It is now generally accepted that free radicals can exert 
cellular damage through a variety of mechanisms  e.g.peroxidation, covalent binding, depletion 
of glutathione and protein thiols, derangement intracellular free calcium homeostasis, DNA 
fragmentation etc.,  
 
 
 
Estimation of phenolic and total flavanoid content 
A phenol comprises the largest group of plant secondary metabolites. They range from simple 
structures with only one benzene ring to larger molecules such as tannins, anthraquinones, 
flavonoids and Coumarin. They are defined as compounds that have at least one hydroxyl group 
attached to a benzene ring, Phenolic compounds are plants and they have been reported to have 
multiple biological effects, including antioxidant activity. 
The word 'Flavonoids' is derived from the Latin word flavus meaning yellow and many 
flavonoids are indeed yellow in color. It consists of a single benzene ring joined to a 
benzogamma-pyrone structure. They are able to complex metal ions, acts as antioxidants and 
bind to proteins such as enzymes and structural proteins. The different classes with in the groups 
are distinguished by additional oxygen containing heterocyclic rings and hydroxyl groups. These 
include the catechins, anthocyanidins, flavanols, flavones and isoflavones. 
3.1. INVITRO STUDY 
ANTIOXIDANT STUDIES:  
Free radicals are atoms or groups of atoms with an odd (unpaired) number of electrons and can 
be formed when oxygen interacts with certain molecules. Once formed these highly reactive 
radicals can start a chain reaction, like dominoes. Their chief danger comes from the damage 
they can do when they react with important cellular components such as DNA, or the cell 
membrane. Cells may function poorly or die if this occurs (Khandalwal KR) 
 
To prevent free radical damage the body has a defense system of antioxidants. Antioxidants are 
molecules which can safely interact with free radicals and terminate the chain reaction before 
vital molecules are damaged. Although there are several enzyme systems within the body that 
scavenge free radicals, the principle micronutrient (vitamin) antioxidants are vitamin E, beta-
carotene, and vitamin C. Additionally, selenium, a trace metal that is required for proper function 
of one of the body's antioxidant enzyme systems, is sometimes included in this category. The 
body cannot manufacture these micronutrients so they must be supplied in the diet.  
Vitamin E : d-alpha tocopherol. A fat soluble vitamin present in nuts, seeds, vegetable and fish 
oils, whole grains (esp. wheat germ), fortified cereals, and apricots. Current recommended daily 
allowance (RDA) is 15 IU per day for men and 12 IU per day for women (Khandalwal KR) 
Vitamin C : Ascorbic acid is a water soluble vitamin present in citrus fruits and juices, green 
peppers, cabbage, spinach, broccoli, kale, cantaloupe, kiwi, and strawberries. The RDA is 60 mg 
per day. Intake above 2000 mg may be associated with adverse side effects in some individuals 
Beta-carotene is a precursor to vitamin A (retinol) and is present in liver, egg yolk, milk, butter, 
spinach, carrots, squash, broccoli, yams, tomato, cantaloupe, peaches, and grains. Because beta-
carotene is converted to vitamin A by the body there is no set requirement. Instead the RDA is 
expressed as retinol equivalents (RE), to clarify the relationship. (NOTE: Vitamin A has no 
antioxidant properties and can be quite toxic when taken in excess) (Khandalwal KR) 
DPPH radical scavenging activity:  
The effect of ethanol fraction of B.Rubra on DPPH radical was estimated by (Lin et al, 2003) 
with minor modification. In brief, 2ml of DPPH in methanol (3.6 × 10-5 M) were added to 50 𝜇L 
of various concentrations test substance (25𝜇l-1ml). The mixture was vortexed for 15 sec and left 
to stand at 37℃ for 30 min. the decrease in the absorbance at 517 nm was continuously recorded 
in a spectrophotometer for 15 min at room temperature. All determination was performed in 
triplicate. The DPPH scavenging activity (decrease of absorbance at 517 nm) of extract was 
plotted against time and the percentage of DPPH radical scavenging ability of the sample was 
calculated from the absorbance value at the end of 15 min duration as follows, 
 
 
         % Inhibition = ( Abs Control–Abs Sample ) × 100/AbsControl 
 
 
Where,  
Abs Control is absorbance of control at time = 0  
Abs Sample is absorbance of test sample at time =15 min. 
Concentration  Silymarin Ethanolic 
extraction 
100μg/ml  20.297±0.01  9.14±0.00  
200 μg/ml  32.657±0.31  38.72±0.21  
400 μg/ml  47.403±0.25  63.41±0.25  
600 μg/ml  57.052±0.66  72.26±0.02  
800 μg/ml  72.0840±0.79  79.34±0.45  
1000 μg/ml  78.261±0.52  80.14±0.16  
   
IC50 Value  585(μg/ml)  305 (μg/ml)  
 
 
 Graph of DPPH scavenging activity 
S indicates Silymarin 
EEBR-Ethanolic extract of Basella Rubra 
Report:  
In the DPPH radical scavenging assay DPPH radical was used as a substrate to evaluate free 
radical scavenging activity of Ethanolic extraction of Basella rubra. This involves the reaction 
between the specific antioxidant and the 2,2diphenyl picryyl hydrazide (DPPH). Silymarin was 
used as a standard. As a result there is a reduction of DPPH concentration by the antioxidant 
principle present in the extract which was confirmed by optical absorbance of DPPH; this was 
detected by spectrophotometer at 517nm.  
 
 
 
4. HERBAL DRUGS 
Herbal wealth of India 
Now-a-days natural products are an integral part of human health care system, because there is 
popular concern over toxicity and resistance of modern drugs. India is one of the 12 leading 
biodiversity centers with presence of over 45,000 different plant species, 15000-18000 flowering 
plants, 23,000 fungi, 16,000 lichens, 18,000 bryophytes and 13 million marine organisms. From 
this flora, 15,000 to 20,000 have good medicinal value. Among those only about 7,000 plants are 
used in Ayurveda, 600 in Siddha, 700 in Unani and 30 in modern medicines. 
Researches in isolated plant constituents are of greater importance, it has given rise to many of 
the world‟s most useful drugs. Tubocurarine, the most powerful muscle relaxant, in existence is 
derived from curare and the strongest pain killer of all, morphine comes from poppy cocaine 
from coca. 
Diseases always co existed with livings, detecting their remedies also always continuing, going 
through the commencement of drug therapy for disease, drug comes to the force in sudden, in the 
ancient time human knowledge found the absence of some forms the base for the development of 
some disease, they were tried to use the particular disease and they got success in that work. 
These motivate the plant researches to use different plants, plant parts for different disease. 
Our traditional system of medicines siddha categorized nearly 5000 plants species and their 
usage. Later on the allopathic system of medicine comes to force and dominate the siddha and 
due to the fast relieving nature it reaches the world as quickly and diminished the usage of plant 
medicine as maximum. 
 But allopathy system cannot provide ultimate solution to some diseases, and also their 
side effect in particularly the long term therapy, limits their usage still plant medicine is 
recommended and usage still the plant medicine is recommended and used in such cases. This 
suggests the plant medicine to researches as and scientific world as alternate to allopathy system 
of medicine. The world health organization also recognize and motivate the plant researches and 
centre, hence the plant medicine now considered to be alternative system of medicine. 
 Even usage of plants are known since plants species consist of mixture of compound, 
isolating the single compound and identifying the component is responsible for that particular 
activity is a major question in front of plant researches and  also it is very difficult to say only 
these are all the compounds available from particular plant. 
 Now days due to the development of science and technology such as chromatography 
technique and spectroscopical technique it is possible to isolate almost all the components of 
plant and characterize them. Isolating and characterization are very important to improve 
effectiveness, minimizing the dose and on set of action. 
3.2.1. A Review of Plants Used in the Treatment of Liver Disease 
In recent years many researchers have examined the effects of plants used traditionally 
by indigenous healers and herbalists to support liver function and treat diseases of the liver. In 
most cases, research has confirmed traditional experience and wisdom by discovering the 
mechanisms 
and modes of action of these plants as well as reaffirming the therapeutic effectiveness of 
certain plants or plant extracts in clinical studies. 
Several hundred plants have been examined for use in a wide variety of liver disorders. 
Just a handful have been fairly well researched. The latter category of plants include: Silybum 
marianum (milk thistle), Picrorhiza kurroa (kutkin), Curcuma longa (turmeric), Camellia 
sinensis(green tea), Chelidonium majus (greater celandine), Glycyrrhiza glabra (licorice), and 
Allium sativum(garlic) 
 
Hepatoprotective natural plants used to treat liver disease 
Some of the crude drugs with activity against liver diseases are: 
• Eclipta Alba (Asteraceae), 
• Glycyrrhiza glabra (Leguminosae), 
• Boerhaavia diffusa (Nyctaginaceae),  
• Phyllanthus amarus (Euphorbiaceae), 
• Silybum marianum (Compositeae),  
• Uncaria gamber (Rubiaceae),  
• Andrograhis paniculata (Acanthaceae). 
 
Some of the reported constituents with pharmacologically/ therapeutically proved claims may be 
enlisted as, was also reported for its hepatoprotective properties. 
 
• Silymarin 
• Glycyrrhizin 
• (+) –Catechin  
• Saikosaponins 
• Curcumin  
• Picrolive I and II 
• Gomosin(Wagner et al.,1998) 
• Acetylbergenin (Lim et al.,2000) 
• Kolaviron (Oluwatosin and Edward, 2006)  
 
Silybum marianum: 
 
• Silybum marianum is currently the most well researched plant in the treatment of liver disease. 
• Also use in the dyspepsia, disorders of biliary system, liver disorder. 
• It is used as Hepatoprotective and in chronic inflammatory hepatic disorders including 
hepatitis, cirrhosis and fatty infiltration which occur due to industrial pollutants and alcohol. 
• It has also been found to be effective against liver poisioning due to alpha-galactosamine, 
carbon tetrachloride and tioacetamide. 
• It has reported that therapeutic utility of silymarin is due to stabilization of cell membrane, 
stimulation of protein synthesis and accelerating the process of regeneration of hepatic cells. 
• The mechanism of Hepatoprotective effect of silymarin has been suggested variously like 
antioxidant activity by trapping superoxide anions, stimulation of RNA synthesis and in case of 
amanita phalloides poisioning, blocking the receptor sites of outer liver cell membranes 
• Silymarin is preferably given by parental route, due to low water solubility of flavonoligans if 
taken orally, only 20-50% is absorbed.  
 
 
 
2). Taraxacum officinale: 
 
• Hepatic & biliary disorders, kidney stones. 
• Traditionally taraxacum officinale has been used as a remedy for jaundice and other disorders 
of the liver and gallbladder, and as a remedy for counteracting water retention. 
• Generally, the roots of the plants have the most activity regarding the liver and gallbladder. 
• Oral administration of extracts from the roots of taraxacum officinale has been shown to act as 
a cholagogue, increasing the flow of bile. 
• Action: diuretic, tonic. 
 
3). Cichorium intybus:  
It is commonly known as kasni and is part of polyherbal formulations used in the treatment of 
liver diseases.  
• In mice, liver protection was observed at various doses of Cichorium intybus but optimum 
protection was seen with a dose of 75 mg/kg given 30 minutes after CCl4 intoxication.  
• In preclinical studies an alcoholic extract of the Cichorium intybus was found to be effective 
against chlorpromazine-induced hepatic damage in adult albino rats 
 
4). Solanum nigrum: 
 
Aromatic water extracted from the drug is widely prescribed by herbal vendors for liver 
disorders.  
• Although clinical documentation is scare as far as Hepatoprotective activity is concerned, but 
some traditional practitioners have reported favorable results with powdered extract of the plant.  
• It is in treatment of cirrhosis of the liver. 
• Also used as a emollient, diuretic, antiseptic, and laxative properties. 
• Antimicrobial, antioxidants, cytotoxic properties. 
• It is also have antiulcerogenic activity and Hepatoprotective activity. 
 
 
 
5). Glychyrrhiza glabra: 
 
Glycyrrhizin use for anti-viral.  
• It has potential for therapeutic use in liver disease. 
• Experimental hepatitis and cirrhosis studies on rats found that it can promote the regeneration 
of liver cells and at the same time inhibit fibrosis.  
• Glycyrrhizin can alleviate histological disorder due to inflammation and restore the liver 
structure and function from the damage due to carbon tetrachloride. 
• The effects including: lowering the SGPT, reducing the degeneration and necrosis and 
recovering the glycogen and RNA of liver cells.  
• Effects of glycyrrhizin has been studied on free radical generation and lipid peroxidation in 
primary cultured rat hepatocytes. 
• Favorable results have been reported in children suffering from cytomegalovirus aftrer treating 
with glycyrrhizin. 
 
3.2.2. Hepatic injury 
 
Ethanol is hepatotoxic through redox changes produced by the NADH generated in its oxidation 
via the alcohol dehydrogenase pathway, which in turn affects the metabolism of lipids, 
carbohydrates, proteins and purines. Ethanol is also oxidized in liver microsomes by an ethanol-
inducible cytochrome P-450 which contributes to ethanol metabolism and tolerance and activates 
xenobiotics to toxic radicals thereby explaining increased vulnerability of the heavy drinker to 
industrial solvents, anesthetic agents,  commonly prescribed drugs over the counter analgesics, 
chemical carcinogens and even nutritional factors such as vitamin A. Induction also results in 
energy wastage and increased production  of acetaldehyde. Acetaldehyde, in turn causes injury 
through the formation of protein adducts, resulting in antibody production, enzyme inactivation, 
decreased DNA repair and alterations in microtubules, plasma membranes and mitochondria 
with a striking impairment of oxygen utilization. Acetaldehyde also causes glutathione depletion 
and lipid peroxidation and stimulates hepatic collagen synthesis, thereby promoting fibrosis.( 
Liebercs;1990) 
 
Mechanism of action of liver injury 
Alcohol also activates Kupffer cells sensitized by lipopolysaccharides {Enomoto et al.,1998} 
which promotes the production of proinflammatory cytokines, such as tumour necrosis factor 
[TNF]alpha, IL-1beta and IL-6 [McClain, Barve, Deaciuc, Kugelmas & Hill, Thurman et al., 
1999; Tilg & Diehl,2000]. Overproduction of pro-inflammatory cytokines is known to play a 
critical role in the development of alcohol-induced liver injury by contributing to hepatocyte 
dysfunction, apoptosis and characteristic fibrosis [Bataller & Brenner, 2005; Neuman,2003] 
Alcohol treatment results in increases in the release of endotoxin from gut bacteria and 
membrane permeability of the gut to endotoxin or both. Females are more sensitive to these 
changes. Elevated levels of endotoxin activate kupffer cells to release substances such as 
eicosanoids, TNF-alpha and free radicals. Prostaglandins increase oxygen uptake and most likely 
are responsible for the hypermetabolic state in the liver. The increase in oxygen demand leads to 
hypoxia in the liver and on reperfusion, alpha-hydroxyethyl free radicals are formed which lead 
to tissue damage in oxygen-poor pericentral regions of the liver lobule. 
It was reported that alcohol stimulates a pro-inflammatory mediator in the liver by increasing the 
production of nitric oxide, an important cause of inflammation. 
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6. PLANT INTRODUCTION 
  
Basella rubra: 
Basella rubra L. (Basellaceae), commonly known as Indian or Malabar spinach belongs to family 
Basellaceae, is an herbaceous annual or biennial climbing herb found in tropical and sub-tropical 
areas. It is a succulent, branched, smooth, twining herbaceous vine, several meters in length. 
Stems are purplish or green. Leaves are fleshy, ovate or heart-shaped, 5 to 12 cms long, stalked, 
tapering to a pointed tip with a cordate base. Fruit is fleshy, stalkless, ovoid or spherical, 5-6 mm 
long, and purple when mature and contain only one seed and the flowers are pink.(Manju Singh 
et al; 2016) 
 
Fig 9: Basella rubra 
Scientific classification: 
Kingdom: Plantae 
Clade: Angiosperms 
Clade: Eudicots 
Order: Caryophyllales 
Family: Basellaceae 
Genus: Basella 
Species: B. alba 
Binomial name Basella Alba L. 
Synonyms 
Bengali- poi 
Hindi- poi, poy, poi shak 
Kannada- Basale 
Marathi- Poi, Basala 
Tamil- Shivappu-vasla-kire 
Telugu- Batsal 
 
Fig 10: Dried leaves of basella rubra 
 
 
Fig 11: Powdered leaves 
 
Organoleptic Character (Maheswari JK) 
Sparsh (Touch)- Snigdha (smooth) 
Rupa (Apperance) – Dark green 
Rasa (Taste) - Madhura 
Gandha (Smell) - No particular smell 
Chemical Constituents: 
The plant contains calcium 2.32, potassium 5.8, magnesium 0.06, sodium 5.11, iron 
0.04mg/100gm. the leaves of the plant contain flavonoids (133.1±26.2 mg QC /100 g FM), β- 
cyanin and 7, 4΄_ di–ortho methyl kempferol. The flower contain phenolic compounds 
(269.0±3.1mg GAE/100 g FM) such as Rutin, Quercetin, Scopoletin, Coumarin, β-xanthin and 
β-cyanin pigments and Caffeic, Homo-protocatechuic-, Chlorogenic-, trans- and cis-p-coumaric-,  
p-hydroxy-benzoic-, phloretic-, trans- and cis-sinapic-, cinnamic- acids; and  the fruit consists of  
β-cyanin, gomphrenin І, gomphrenin II, and gomphrenin III.( Tanu shekhawat;2008) 
The chemical composition of the leaf extract has been found to be: proteins, fat, vitamin A, 
vitamin C, vitamin E, vitamin K, vitamin B9 (folic acid), riboflavin, niacin, thiamine and 
minerals such as calcium, magnesium and iron. Some unique constituents of the plant are 
basellasaponins, kempferol and betalain.(shruthi et al;2014) 
Therapeutic uses 
Basella rubra has been used from a long time back for the treatment of many diseases like 
dysentery, diarrhea, anemia, cancer. 
The paste of root of red B. rubra along with rice washed water is taken in the morning in empty 
stomach for one month to cure irregular periods. Leaves are used in the treatment of 
hypertension. The plant has been reported for its antifungal, anticonvulsant, analgesic, anti-
inflammatory and androgenic activities and for the treatment of anemia. The leaves are 
traditionally used in ayurveda system of medicine to bring sound refreshing sleep when it is 
applied on head about half an hour before bathing.  A paste of the root is applied to swellings and 
is also used as a rubefacient. Sap is applied to acne eruptions to reduce inflammation. Decoction 
of leaves used for its mild laxative effects. (Shruthi et al; 2014) 
For snakebites, crushed plant is applied topically at place of bite. Juice of leaves is used to get 
relief from constipation in pregnant women and a decoction has been used to alleviate 
labour.This is also useful in gonorrhea and balanitis (inflammation of the end of the 
penis).(Anupama;2015) 
Antimicrobial Activity 
This study has revealed the presence of secondary metabolites like Steroids and triterpenoids in 
the leaves and stem of Basella rubra. It has further confirmed that the leaf extract could be used 
for the treatment of infections caused by the microorganisms E.coli, Pseudomonas aeruginosa, 
Bacillus subtilis and Aspergillus flavus. (Krishana priya et al; 2015) 
Antidiabetic activity 
Glucose levels were found to be significantly increased after STZ administration, and there after 
decreased by administration of Basella rubra. Decrease in serum glucose may be due to the 
regeneration of beta cells of the pancreas, which were destroyed by STZ. Administration of 
Basella rubra extract produced a significant (p<0.01> decrease in the blood glucose as compared 
to diabetic rats. (Nirmalax A et al; 2011) 
Antiulcer activity 
The aqueous extract of B. rubra possesses significant and dose dependent anti-ulcer and 
cytoprotective effects against ethanol and pylorus ligated induced ulcer rats and the study was 
compared with ranitidine (50 mg/kg p.o.) as standard drug. It concludes the results indicate the 
aqueous extract of Basella rubra in the treatment of gastric ulcers. (S. Deshpande et al; 2003) 
 
 
 
 
 
  
 
 
 
 
7. MATERIALS AND METHODS 
Materials 
The experimental plants were the leaves of Basella rubra. 
Collection and identification of the tested plants 
Basella rubra 
 Basella rubra leaves were procured on December 2016 from plants growing in south india of 
theni, and dried at room temperature.  
The seeds of Basella rubra (Basallaceae) were collected from local source, Tamil Nadu 
(Chennai) in the month of March. The leaves were identified and authenticated by Prof. 
P.Jayaraman, Retd Professor of Presidency College and Director of Institute of Herbal Science 
Plant Anatomy Research Centre, West Tambaram, Chennai-600045. A voucher specimen was 
deposited at C.L.Baid Metha College of Pharmacy for future reference.  
Preparation of extracts of Basella rubra 
Extraction involves the separation of bioactive portion of the plant tissues from the inactive 
components by using selective solvents in standard extraction procedure. 
The powdered leaves (500g) were extracted by using acetone by sequentially extracted using 
petroleum ether, chloroform, acetone and ethanol in Soxhlet apparatus. Where as a known 
weight of the coarsely powdered part of each plant was extracted successively with chloroform 
(60 -80 c°) and ethanol (98%) using soxhlet extractor. The chloroform extract was kept a side 
and the ethanolic extracts were filtered, evaporated, dryness using Rota vapor apparatus (under 
reduce pressure), and the yields were calculated. The residue obtained was kept in dry clean 
bottles till used (Harborne, 1973). 
 
7.1. PRELIMINARY PHYTOCHEMICAL STUDIES: 
 
The various extracts Basella rubra of obtained were subjected to qualitative analysis to test the 
presence of various phytochemical constituents like alkaloids, carbohydrates, glycosides, 
flavonoids, steroids, terpenoids, phenols, proteins, tannins etc.  
 1. Tests for Alkaloids  
Mayer‟s test  
A pinch of dried extracts was taken and 2 ml of dilute hydrochloric acid was added, mixed 
filtered. To the filtrate, one or two drops of Mayer‟s reagent were added. Formation of pale 
yellow precipitate indicates the presence of alkaloids. 
Dragendorff‟s test  
A pinch of dried extracts was taken treated with 2ml of 2% Acetic acid, mixed thoroughly and 
filtered. To the filtrate 2 drops of Dragendorff‟s reagent was added. Formation of orange-brown 
precipitate indicates the presence of alkaloids.  
Hager‟s test  
A pinch of dried extracts was taken and treated with drops of Hager‟s reagent. Formation of 
yellow precipitate indicates the presence of alkaloids.  
Wagner‟s test  
A pinch of dried extracts was taken and treated with drops of Wagner‟s reagent. Formation of 
brown precipitate indicates the presence of alkaloids  
2. TESTS FOR SUGAR AND CABOHYDRATES  
Molish‟s test  
       A small quantity of extracts was dissolved separately in 4ml of distilled water and filtered. 
Filtrate was treated with 2-3 drops of 1% alcoholic 𝛼-napthol solution and 2ml of concentrated 
sulphuric acid was added from the sides of the test tube. Brown ring at the junction of two 
liquids indicates the presence of carbohydrate.  
3. TESTS FOR GLYCOSIDES  
Anthrone test  
     A pinch of extracts was taken in a watch glass and 2 drops of alcohol was added to extract. 
An equal quantity of anthrone was added and mixed thoroughly and dried. Then one drop of 
concentrated sulphuric acid was added, separated in a thin film with a glass rod in a watch glass. 
and heated over the water bath. Formation of dark green color indicates the presence of 
glycosides.  
Test for anthraquinone glycosides  
Borntrager‟s test  
A pinch of the extracts was boiled with dilute sulphuric acid, filtered while hot and filtrate was 
extracted with solvent like benzene. It was shaken well and the organic layer was separated and 
to this equal volume of dilute ammonia was added. Rose pink colour in ammonia layer indicates 
the presence of anthraquinone glycoside.  
Test for cardiac glycosides  
Legal‟s test  
     The extracts were hydrolysed for few hours in a water bath. The hydrolysate was added with 
2ml of pyridine, sodium nitropruside solution and was made alkaline with sodium hydroxide 
solution. Orange colour shows the presence of cardiac glycoside.  
4. TESTS FOR PROTEINS  
Small quantity of extracts was dissolved in a few ml of water and subjected to the following test:  
Biuret test  
     To the extract solution few drops of biuret reagent (1%CuSO4 and 10% NaOH), 1 drop of 
Copper sulphate solution and 10 drops of sodium hydroxide solution were added. Purple or 
violet color shows the presence of proteins.  
Million‟s test  
         Few drops of Million‟s reagent were added to the extract solution. Reddish brown color 
shows the presence of proteins.  
5. TESTS FOR AMINO ACID  
 Ninhydrin test  
        To the extract few drops of Ninhydrin reagent were added. Purple color shows the presence 
of amino acids. 
6. TESTS FOR SAPONINS: 
Foam Test: 
 1 ml of the ethanol extract solutions were taken in a measuring cylinder. To this, 20 ml of 
distilled water were added and shake well. 
Haemolysis Test: 
 The ethanol extracts of the plant were spread over a glass slide to form a thin film layer 
on which a drop of human blood was placed and spread over the extract layer. After 30 minutes, 
the slide was examined under microscope for change in the structure and shape of red blood 
cells. Control was always maintained to see the change in red blood cells structure for 
haemolysis. 
7. TEST FOR GLYCOSIDES 
Small amount of extracts is treated with distilled water and subjected to molish„s test . 
To the extracts is hydrolyzed with dilute hydrochloric acid and subjected to 
Lieberman –burchara‟s, legal‟s and borntrager‟s test to detect presence of different 
glycosides. 
8. TEST FOR REDUCING SUGAR 
A small portion of extracts was dissolved in water and treated with Fehling‟s and Benedict‟s 
reagent to detect presence of sugars. 
9. TEST FOR PHYO STEROLS 
 The extracts were heated with solution of alcoholic potassium hydroxide until complete 
saponification. Then it was diluted with distilled water and extracted with ether. The ethereal 
extract is evaporated and the residue (un saponifiable matter) was subjected to Liebermann‟s and 
Lieberman Burchara‟s test . 
 
 
10. TESTS FOR PHENOLIC COMPOUNDS  
Ferric Chloride Solution test  
The extracts were taken in water and warmed; to this 2ml of Ferric Chloride solution was added. 
Formation of green colour is due to the presence of phenolic compounds  
Lead Acetate Solution test  
To the extracts (2ml) lead acetate solution was added separately. Formation of precipitate 
indicates the presence of phenolic compounds.  
11. TESTS FOR TANINS  
A pinch of the dried extracts was dissolved in ethanol, mixed thoroughly and filtered. The filtrate 
is tested for the presence of tannins by the following test;  
Ferric Chloride  
To the filtrate dilute Ferric chloride solution was added.Formation of greenish blue precipitate is 
due to presence of tannins.  
 Lead Acetate  
To the filtrate lead acetate solution was added(10%). Formation of white colour precipitate is due 
to the presence of tannins. 
 Gelatin Solution  
To the filtrate 1% solution of gelatin solution containing 10% Sodium Chloride was added. 
Formation of white colour precipitate is due to the presence of tannins.  
TESTS FOR TERPENOIDS  
Noller‟s test or Salkowshi test  
A pinch of dried extract in a test tube was taken and a bit of Tinfoil and 0.5 ml of thionyl 
chloride was added. It was heated gently. Formation of the pink colour is due to the presence of 
terpenoids.  
11. DETERMINATION OF FIXED OILS AND FATS  
Spot test  
A small quantity of various extracts was pressed separately between two filter papers. Oil stain in 
the filter paper indicates the presence of the fixed oils.  
12. TESTS FOR STEROIDS  
Liebermann‟s Burchard test  
The extract were dissolved in 2ml of chloroform and 10 drops of acetic anhydride, 2 drops of 
concentrated sulphuric acid were added. Formation of green colouris due to the presence of 
phytosterols.  
Salkowski test  
A extract was treated with chloroform and a few drops of concentrated sulphuric acid was added 
along the sides of the test tube. The lower layer of the chloroform showed red colour due to the 
presence of steroids. 
Test for gums and mucilage’s 
                    Above 10 ml of aqueous extract was prepared and added to 25 ml of absolute 
alcohol with constant stirring resulting solution is observed for precipitate. 
Test for volatile oil:  
                      The powdered material was subjected to hydro distillation to separate volatile oil if 
present 
7.2. Separation and Isolation of plant Constituents by Chromatographic Methods 
Column chromatography 
Column chromatography is a separation technique, when a column of stationary phase is used. 
the technique is called as column chromatography. Based on the nature of stationary phase, 
whether it is solid or liquid, it is called column adsorption chromatography or column partition 
chromatography. Column adsorption chromatography is widely used technique. 
A. Principle 
A solid stationary phase and a liquid mobile phase are used and the principle of separation is 
adsorption. When a mixture of components dissolved in the stationary phase is introduced in to 
the column, the individual components move with different rates depending upon the relative 
affinities. The compound with lesser affinity towards the stationary phase (adsorbent) moves 
faster and hence it is eluted out of the column first. The one with greater affinity toward the 
stationary phase (adsorbent) moves slower down the column and hence It is eluted later. Thus the 
compounds are separated. The type of interaction between the stationary phase and solute is 
reversible in nature. The rate of movement of a component (R) is given as follows; 
This equation can be simplified as follows:  
                                     Distance travelled by the solute 
Rf value     =              
                                     Distance travelled by the solvent 
Stationary Phase: The stationary phase is one of the two phases forming a chromatographic 
system. It may be a solid, a gel or a liquid. If a liquid, it may be distributed on a solid. This solid 
may or may not contribute to the separation process. The liquid may also be chemically bonded 
to the solid (Bonded Phase) or immobilized onto it (Immobilized Phase). 
Mobile Phase: A fluid that percolates through or along the stationary bed, in a definite direction. 
It may be a liquid (Liquid Chromatography) or a gas (Gas Chromatography) or a supercritical 
fluid (Supercritical-Fluid Chromatography). In gas chromatography the Carrier gas may be used 
for the mobile phase. 
B. Column characteristics 
 The material of the column is mostly good quality neutral glass since solvents, acids or 
alkalies should not affect it. An ordinary burette can also be used as column for separation. The 
column dimensions are important for effective separations. The length-diameter ratio ranges 
from 10:1 to 30:1, For more efficiency the length: diameter ratio can be 100:1. The length of 
column depends upon 
 Affinity of compounds  towards the adsorbent used. 
 Number of compounds to be separated. 
 Type of adsorbent used 
 Quantity of the sample 
C) Column packing material 
The selection of suitable column packing materials is made on the basis of the chromatographic 
process. Based upon their adsorbent activity, they can be classified as weak, medium, strong 
adsorbents. They are 
Weak Medium Strong 
 
Sucrose 
Starch 
Insulin 
Talc 
Na2CO3 
 
CaCO3 
Ca3(PO4)2 
MgCO3 
MgO 
Ca(OH)2 
 
Silica gel 
Activated alumina 
Activated charcoal 
Activated magnesia 
 
D) Solvent selection  
The choice of solvents will naturally depend on the first place upon the solubility relations of 
substance. The solvents commonly used as mobile phase can be arranged according to their 
increasing eluting power. Elutropic series given below serve as guide for sequential solvent 
selection, most of the solvents have sufficient low boiling points to permit ready recovery of 
eluted material. 
Points to be selecting while selecting the solvents 
The polarity of the solvent, which is passed through the column, affects the relative rates at 
which compounds move through the column 
Polar solvents can more effectively compete with the polar molecules of a mixture for the polar 
sites on the adsorbent surface and will also better solvate the polar constituents. 
Highly polar solvent will move highly polar molecules rapidly through the column. 
If a solvent is too polar, movement becomes too rapid, and little or no separation of the 
components of a mixture will result 
If a solvent is not polar enough, no compounds will elute from the column 
Solvent Percentage of Extract 
Benzene 0.01% 
Toluene 0.00% 
Dichloromethane 0.00% 
Ethylacetate 0.00% 
Acetone 0.01% 
Methanol 0.01% 
Water .0002% 
 
7.3. Physiochemical analysis  
ASH VALUE: (Peter S et al; 2001) 
This parameter can be used for the determination of inorganic materials such ascarbonates, 
silicates, oxalates and phosphates. Heating causes the loss of organic material in the form of 
carbon dioxide leaving behind the inorganic components. Ash value is an important 
characteristic of a drug and with the help of this parameter we can detect the extent of 
adulteration as well as establish the quality and purity of the drug. There is considerable 
difference in the ash values of different drugs but mostly the difference varies within narrow 
limits in case of the same drug. The acid insoluble ash consists mainly of silica and high acid 
insoluble ash thereby indicating the contamination with earthy materials. The water-soluble ash 
is used to estimate the amount of inorganic elements.  
Determination of total ash  
About 2gm of air-dried crude drug were weighed accurately in a tarred platinum or silica dish 
and was incinerated at a temperature not exceeding 450°C until free from carbon. It was then 
cooled and weighed. The percentage of ash was calculated with reference to the air-dried drug.  
Determination of Water-soluble ash  
The total ash was boiled for 5 min. with 25ml of water. The insoluble matter was collected in a 
Gooch crucible or an ash less filter paper. It was washed with hot water and ignited for 15min., 
at a temperature not exceeding 450°C. The weight of the insoluble matter was subtracted from 
the weight of the ash. The difference in the weight of the ash represents the water-soluble ash. 
The percentage of water-soluble ash was calculated with reference to the air-dried drug.  
Determination of Acid insoluble ash  
The ash was boiled with 25ml of 2M HCl acid for 15min. the insoluble matter was collected in a 
Gooch crucible or an ash less filter paper. It was washed with hot water and ignited. It was then 
cooled in desiccators and weighed. The percentage of acid insoluble ash was calculated with 
reference to the air-dried drug.  
EXTRACTIVE VALUES:  
The amount of an extract that a drug yields in a particular solvent is often an approximate 
measure of the amount certain constituents that the drug contains. The drug should be extracted 
with different solvents in order of their increasing polarity to get the correct and dependable 
values. Generally petroleum ether, alcohol and water extractives are taken into consideration for 
fixing the standard of a drug. The petroleum ether extract contains fixed oil. Resin and volatile 
substances, but when the extract is heated at 105℃ until constant weight, the volatile substances 
are volatized only resin, colorings matter and fixed oil. Alcohol can dissolve almost all the 
substances but is generally used for determining the extractive index for those drugs which 
contain glycosides, resins, alkaloids etc. Water is used for the drugs containing water-soluble 
substances as chief constituents.  
 Water soluble extractive  
 Alcohol soluble extractive  
Determination of water-soluble extractive  
5gm of the powder was macerated with 100ml water in a closed flask for 24 hours, shaking 
frequently for 6 hours and allowing standing for 18 hours. It was filtered and 25ml of the filtrate 
was evaporated to dryness at 105℃ and weighed. The percentage of water-soluble extractive was 
calculated with reference to the air-dried drug.  
Determination of alcohol soluble extractive  
5gm of the powder was macerated with 100ml alcohol in a closed flask for 24 hours, shaking 
frequently for 6 hours and allowing standing for 18 hours. It was filtered rapidly taking 
precautions against loss of alcohol and 25ml of the filtrate was evaporated to dryness at 105℃ 
and weighed. The percentage of alcohol-soluble extractive was calculated with reference to the 
air-dried drug.  
Determination of loss on drying 
This parameter is used for determination of moisture content. Loss on drying is the loss in  
weight in %w/w determined as per the following procedure:  
Procedure:  
A weighed stopper glass bottle that has been dried for 30 minutes under the same conditions to 
be employed in the determination was weighed. The sample was placed into thebottle and the 
contents were accurately weighed. The sample was distributed evenly to depth no exceeding 10 
mm. the loaded bottle was placed in a drying chamber (oven) and the stopper was removed. The 
sample was dried to constant weight at a temperature of 110℃ in hot air oven. The percentage of 
loss on drying was calculated with reference to the air-dried drug. 
Swelling index  
1 gm of the bud was soaked in water for 24 hours and then its weight was weighed again. The 
swelling index is calculated by using the formula,  
Swelling index = Weight after soaking 
                Weight before soaking 
 
7.4. Instruments and chemicals: 
A wide range of instruments and chemicals were used during the course of this 
Study as follow: 
Instruments: 
• Soxhlet apparatus Quick FIT, EX5/83. ENGLAND. 
• Water bath BUCHI 461 SWITZERLAND 
• Sensitive balance HF-300G A&D COMPANY, Limited 
• Haemacytometer Hawksley, ENGLAND. 
• Capillary tubes 
• condenser  
• Rota vapor apparatus 
 
 
Chemicals 
Ethanol Absolute  
Petroleum ether  
Silymarin 
 SGOT enzyme Kit (Giri diagnostic kit pvt ltd) 
SGPT enzyme kit (Giri diagnostic kit pvt ltd) 
Chloroform (Central drug house pvt ltd) New Delhi 
7.4.1. Mechanism of Action of silymarin 
The mechanisms which provide silymarin hepatoprotective effects are many and varied, and 
include antioxidation, anti-lipid peroxidation, enhanced detoxification, and protection against 
glutathione depletion. (Halim AB et al; 1997) 
Stimulation of Liver Regeneration: 
One of the mechanisms to explain the ability of silymarin to stimulate the regeneration of hepatic 
tissue is the increase in protein synthesis in damaged livers. In both in vivo and in vitro 
experiments, significant increases in the formation of ribosome and DNA synthesis were 
measured in addition to the increase in protein synthesis. Interestingly, the increased protein 
synthesis was only measured in damaged livers (partial hepectomy), not in controls.35 The 
mechanism of increased protein synthesis is currently not known but some authors speculate 
silymarin imitates a physiologic regulator, so the silybin fits into a specific binding site on the 
polymerase, thus stimulating ribosome formation. (Schopen RD et al; 1969) 
The potential for stimulation of protein synthesis by silymarin was investigated in malignant 
liver tissue, and no increases in protein synthesis, ribosome formation, or DNA synthesis were 
found in malignant cell lines. (Sonnenbichler J et al; 1986)  
7.4.2. Alcohol hepatotoxicity 
Alcohol is one of the main causes of end-stage liver disease worldwide In the United States, 
alcoholic liver disease is the second most common reason for liver transplantation (Mandayalu 
Jamal et al 2004). The Dionysus Study, a cohort study of the prevalence of chronic liver disease 
in an Italian population showed that 21% of the population studied was at risk for developing 
liver damage. Of these, only 5.5 % of the individuals at risk showed actual Signs of liver 
damage. 
About 50 years ago it was believed that alcohol in itself was not toxic, rather that the nutritional 
deficiencies often accompanying it mere the actual causes of liver damage. However, It was 
shown by Lieber and De Carli that in rats, alcoholic liver damage developed despite suffcient 
nutrition (DeCarli and Lieber; 1967). The toxicity of alcohol was later on shun to be related to its 
metabolism by alcohol dehydrogenases (ADHs) and also to the metabolism by CYP2E1. There is 
also a component of metabolism by catalase (Zilna, Fialova et al. 2001) The main pathway for 
ethanol (EtOH) oxidation in die liver IS ADH to acetaldehyde, which is associated with the 
reduction of NAD to NADH NADH increases in  xanthine oxidase activity, which elevates 
production of superoxide Fialova et al 2001). Metabolism of EtOH by alcohol dehydrogenase 
Influences the redox status of the liver also in other ways. Enhanced acetaldehyde production 
after EtOH metabolism decreases hepatic glutathione (GSH) content. The decrease in GSH both 
due to an increased loss, as well as a lower rate of synthesis (Speisky, MacDonald et al 1985). 
The absolute majority of EtOH oxidation is by ADH to acetaldehyde and by aldehyde 
dehydrogenase to acetic acid. However, there is a slight of P450 dependent inducible EtOH 
oxidation due to the CYP2E1 component. Also, CYP1A2, CYP3A4 and CYP2B families may 
contribute to EtOH oxidation (Johansson, Ekstrom et al. 1988; Lieber 2004).  
The first indication that not only alcohol dehydrogenases participate m the metabolism of ethanol 
came in the early 1970's, when it was discovered that microsomal membrane fractions were 
capable of catalyzing the oxidation of ethanol. These reactions required NADPH and were 
inhibited by CO, properties that are distinct from those of alcohol dehydrogenases (Liber. Rubin 
et al;1970). It was then discovered that this activity was due to CYP2E1 and that the enzyme was 
inducible by ethanol in rats (Ryan Koop et al. 1986; Johansson Ekstrom et al. 1988) 
Free radicals have been implicated in alcoholic liver disease in various ways. Mechanism that are 
thought to be Involved are impairment of antioxidant defenses, as well as production of reactive 
oxygen by flie mitochondria and the CYP2E1 enzyme, and by activated phagocytic cells. 
Oxidative compounds then may lead to activation of immune cells to express pro-fibrotic and 
pro-Lnflam_matoly cytokines. Macrophages produce TNTa In various conditions that cause 
oxidative stress (Ahmed, Aronson et al. 2000), as well as IL-1 and IL-6 (Meng and Lowell 
1997). Also, oxidative stress leads to the generation of lipid peroxidation products and protein 
adducts (Ekstrom and Inge1man-Sundberg 1989; Dupont, Lucas et al 1998; Johansson and 
Inge1man-Sundberg 1985; Albano, French et al 1999), which eventually stimulate a break in 
self-tolerance and all immune reaction associated with hepatitis (Albano 2006). CYP2E1 
Inhibitors have been shown to reduce the formation of lipid peroxidation products (Inge1man-
Sundberg Johansson et al 1993). CYP2E1 has also been should be elevated in non-alcoholic 
steatohepatltis (Weltman, Farrell et al. 1998). Furthermore it has been shown that the increase m 
cellular oxidative stress by even moderate alcohol consumption may be one of the mechanisms 
by which alcoholism progression of chronic hepatitis C, as antibodies towards albumin adducted 
with lipid peroxidation products were greater in consumers (Riga-monti, Mottaran et al; 2003). 
It was suggested that CYP2E1 may play a role in alcoholic liver damage as it has been shovm 
that during ethanol oxidation CYP22E1 produces  O2 -and H202 as a result of uncoupling of 
oxygen consumption with NADPH oxidation (ingeman-Sundberg and Johansson 1984). In the 
presence of iron catalysts, even more reactive oxygen species (ROS) can be formed, such as the 
hydroxyl radical, superoxide and hydrogen peroxide(Ingeman-Sundberg and Johansson 1984; 
Gonzalez 2005; Cederbaum 2006 and Ingeman-Sundberg 1989); Kou Galeotti et al. 1991). These 
reactive oxygen species (ROS) may lead to elevated levels of lipid peroxidation products, that in 
turn adducts with cellular proteins. Adducts may also be formed with nucleic acids. Eventually, 
this will result In cell damage (Cederbaum 2006) It has been shown that the vanous lipid 
peroxidation products formed lead to an Immune response in human alcoholics, which worsens 
as disease progresses (Mot-taraw Stewart et al. 2002). Lipid peroxidation products have also 
been shown to play a part in fibrosis, by able to activate the stellate cells of die liver to increase 
their production of collagen which has been particularly studied for the lipid aldehyde malondi 
aldehyde(MDA) (Maher, Tzagarakis et al. 1994). 
Liver injury is often zonated within the liver this is the case for many hepatotoxins that primarily 
damage the perivenous region and also true in the case of ethanol. Notably, ChQ2E1 is 
particularly induced in regions by ethanol (Johansson Lindros et al. 1990; Fang, Lindros et al. 
1998). vitro studies using HepG2 cells transfected to express CYP2E1, both stably and 
transiently, have show signs of DNA fragmentation and cell death in transfected cells, which is 
not seen in controls. EtOH-induced apoptosis was prevented by an Inhibitor of ethanol oxidation 
Via CP2E1, and also by an antioxidant that prevents lipid peroxidation (wuand Cederbaum 1999) 
In this cell model it was also noted that glutathione levels were lowered (Wu and Cederbaum 
2004) 
Although alcohol is undoubtedly a hepatotoxicity still only approximately 20% of heavy drinkers 
(males) develop alcoholic cirrhosis (Lelbach 1975). Cirrhosis is most often preceded by hepatitis, 
generally defined by the following morphologic features; hepatocyte necrosis, neutrophil 
polymorph Infiltrate fatty changes and usually also Mallory bodies (accumulations of hyaline 
material in damaged hepatocytes). The series of events preceding cirrhosis are commonly; fatty 
accumulating hepatitis, fibrosis and finally cirrhosis 
Immunological reactions play a large role in alcoholic liver disease. It has long been known that 
chronic alcoholic liver disease as well as hepatitis is associated with elevated serum cytokine 
levels, which have prognostic value. TNF alpha is associated with increased mortality in 
alcoholics (Yin, Wheeler et al. 1999) Serum levels of TNF Alpha receptor 2 and IL-8 have been 
shown to be significantly elevated in alcoholics (Gonzalez-Reimers, Garcia-Valdecasas-Campelo 
et al. 2007). Liver disease patients have also been shown to have elevated levels of the pro-
inflammatory cytokines IL-6 and IL-8 (Gonzalez-Quintela, Vidal et al. 1999) as well as TNF 
alpha  and IL-2. IL-6 and IL8 are also elevated m alcoholic patients without liver disease. 
Interestingly, also levels of anti-inflammatory cytokines such as IL-IO are elevated in alcoholics 
with liver disease cirrhosis (Latvala& Hietala et al. 2005; Szuster-Ciesielska Damluk et al. 
2000). Clinically, dietary supplementation with SAM to restore glutathione levels, and 
phosphatidylcholines to restore membrane finction have been successful and proved some 
favorable effects on parameters of liver damage (Liebr 2005). S-Adenosy1 methionine (SAM) is 
a precursor of glutathione. The drug N-acetylcysteine NC), also a glutathione precursor, is used 
clinically to prevent hepatic failure in the case of paracetamol overdose (Lauterburg, Corcoran et 
al. 1983; Shah and Gordon 2007). The beneficial effect of SAM has also been shown in vanous 
animal models. In rats exposed to ethanol and LPS, SABA treated animals showed significantly 
decreased fibrosis, oxidative stress and steatosis. Supplementation also improves liver function 
SAM also decreases as TGFß mRNA levels and stellate cell activation (Kapaa 2008) SAM has 
also been proved to attenuate EtOH induced glutathione depletion and associated mitochondrial 
lesions m baboons (Lieber 1994). 
 
7.5. Animals  
Wistar albino rats (150-200g) used in studies was procured from C.L.Baid metha college of 
pharmacy, Chennai-97 The animals were fed with standard pellet diet (Hindustan lever Ltd. 
Bangalore) and water ad libitium. All the animals were acclimatized for a week before use. The 
experimental protocols were approved by Institutional Animal ethics Committee after 
scrutinization. Animals were received the drug by oral gavage tube. All the animals were care of 
under ethical consideration as per the CPCSEA guidelines (CPCSEA, 2003) with regular 
inspections of rats (Sharma A et al; 2012) 
7.5.1. Acute toxicity studies: 
Healthy Wistar albino female rats of sex weighing 100-170 g maintained under standard 
laboratory conditions were used for acute oral toxicity test according to Organization for 
Economic Co-operation and Development guidelines 423. Animals were observed individually 
at least once during first 30 min after dosing, periodically during first 24 h. Observations were 
done daily for changes in skin and fur, eyes, mucus membrane (nasal), respiratory rate, 
circulatory signs (heart rate), autonomic effect (salivation, lacrimation, perspiration, urinary 
incontinence and defecation) and central nervous system (drowsiness, gait, tremors and 
convulsion) changes (Sharma A et al; 2012) 
 
 
 
 
 
 
 
 
 
Determination of acute toxicity (LD50):  
 
 14 days single dose oral acute toxicity and gross behavioral study  
 
Number of animals required:  6 rats (male)  
Number of groups:   2 groups (3 animals each group)  
Dose levels:     4000 mg/kg body weight of the animals.  
Study duration:  14 days  
 
Preparation of dose:  
 
  Ethanolic extract of BASELLA RUBRA leaves was suspended in 3% CMC, to prepare a 
dose of 4000 mg/kg body weight of animal, and administered 1ml/100gm body weight of the 
animal.  
 
 
 Procedure:  
 
  The procedure was divided into two phases, Phase I (observation made on day one), and 
Phase II (observed the animals since next 14 days). Two set of healthy female animal (each set of 
3 rats) were used for the experiment.  First set animals were divided and fasted for 18 hours 
deprived from food, water withdrawn before 4 hours of the dosing, body weights were noted 
before and after dosing with ethanolic extract of Basella rubra (4000 mg/kg) orally. Individually 
animals were observed for 4 hours to see any clinical symptoms, any change in behaviour or 
mortality. 6 hours post dosing again body weights recorded. Form the next day onwards, each 
day for 1 hour the behavioral change, clinical symptoms or mortality was observed in the same 
animals for next 14 days and animal body weights were recorded on 8th and 14th day. The same 
procedure was repeated with another set of animals to nullify the errors. 
 
 
 
 FLOW CHART  
  OECD Guidelines: Test Procedure Starting Dose of 300 mg/kg B.W. 
 
 
START 
 
300 mg/ kg / 3 animals 
 
 
0 - 1 (None of animals died) 
 
 
2000 mg/ kg 
 
 
2 – 3 (None of animals died) 
 
 
3000 mg/kg (none of animals died) 
 
 
4000 mg/ kg / 3 animals 
 
 
None of animals died 
 
 
LD50 cut off 4000 mg/ kg B.W. 
Chemicals  
All the chemicals and solvents were of analytical grade. Silymarin was obtained from silybon, 
Micro Labs, India. Standard kits for SGOT, SGPT and ALP etc. were obtained from Span 
Diagnostics Ltd., India. Male Albino rats weighing between 150-200 gm used in the experiment 
were kept in animal house under standard environmental conditions and had free access to feed 
and water ad libitum. The animals were fasted for 16 hours before experiment but allowed free 
access to water.  
The rats were divided into five groups each containing four rats.  
Group1 Control Received water (5ml/kg. p.o) 
for 21 days once daily, and 
served  as normal control 
Group2   Negative control Received water (5 ml/kg. p.o) 
for 21 days once daily and 
40% ethanol v/v (2.0ml/l00g 
body wt, p.o.) for 21 days. 
Group3 Standard Received 40% ethanol v/v 
(2.0ml/l00g body wt, p.o.) for 
21 days and standard drug 
silymarin (25 mg/kg. p.o.) for 
21 days once daily 
Group4 High dose Received 40% ethanol v/v 
(2.0ml/l00g body wt, p.o.) for 
21 days and Received 
ethanolic extract of Basella 
rubra (400 mg/kg) 21 days 
once daily 
Group4 Low dose Received 40% ethanol v/v 
(2.0ml/l00g body wt, p.o.) for 
21 days and Received 
ethanolic extract of Basella 
rubra (200 mg/kg) 21 days 
once daily 
 
7.5.2. Experimental procedure: 
The rats were weighed after the adaptation period and marked with serial numbers and divided 
randomly into 5 groups, 5 rats each, and then the doses were calculated according to individual 
body weights. 
Blood samples: 
Blood was obtained by puncturing retro orbital plexus (Poole, 1989), under anesthesia using 
Halothane and heparinized capillary tubes. Blood drops were collected, gently, serum was 
separated by centrifugation (2500 rpm for 15 min), and EDTA was used as an anticoagulant for 
hematological parameters. Samples were collected before and after dosing with the tested plants 
extracts at day 0, 5 and at day 10. 
7.5.3. Assessment of liver function: 
Blood sample were collected into dry clean bottles and allowed to clot for 30 min at room 
temperature. Serum separated by centrifugation at 2500 rpm for 15 min and stored at -20c° until 
analyzed. Biochemical parameters, i.e. alanine amino transeferase (ALT), aspartate amino 
transferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL) were analyzed according 
to the reported methods. 
Total Bilirubin: 
Total Bilirubin in serum is determined using the method of Jendrassik and 
Grof, (1938). 
Principle: 
Bilirubin in the presence of a sluphanlic acid diazonium salt from a red colored azo compound in 
alkaline solution. Bilrubin is coupled with diazotized sulfanilic acid in the presence of caffeine to 
give an azo dye. The optical density was measured by spectrophotometer at wave length 546 nm. 
Calculation: 
Total Bilirubin is calculated as follow: 
Absorbance tube Total × 17.5 = Total Bilirubin (mg/dl). 
Alkaline phosphatese: 
It is an optimized method according to recommendation of Chemie (1972). 
Principle: 
In Alkaline medium serum alkaline phosophates splits pnitrophenyl phosphate, 
in the presence of Mg+2 ions, into p-nitro phenyl and 
Phosphate. At the PH of reaction, p-nitrophenyl was colored yellow, the 
optical density measured in a spectrophotometer at wavelength 405nm. 
Reaction: 
P-nitrophenylphosphate + H2o ALP phosphate + p-nitro phenol 
Calculation: 
ALP is calculated as follows: 
U/1 = 2760 × A 405nm/min 
(A = the mean of sample absorbance reading) 
Alanine amino transeferase (ALT): 
It is an enzymatic method, which measure gultamic pyruive transamine in serum according to 
Reitman and Frankel (1957), and Schmidt and Schmidt, (1963). 
Principle: 
Alanine amino transfers is measured by monitoring the concentration of pyruive hydrazone 
formed with 2-4 dinitrophenylhydrazine . 
Reaction: 
α - oxoglutarate + L-alanine ALT L-glutrate + pyruivate 
The absorbance of samples was read against the reagent blank after 5min at 
wavelength 546 nm in spectrophotometer. 
Aspartate amino transferase (AST): 
It is an enzymatic method that measure gultamic oxaloacetic transaminase in serum according to 
Reitman and Frankel (1957), and Schmidt and Schmidt,(1963). 
Principle: 
Aspartate amino transferase is measured by monitoring the concentration of oxaloacetate 
hydrozone formed with 2-4 dintrophenyl hydrazine. 
Reaction: 
α- oxoglutarate +L-aspartate AST L-glutarate + oxaloacetate 
The absorbance of samples was read against the reagent blank after 5min at wavelength 546 nm 
in spectrophotometer and cuvette of 1cm light path. 
Haematological studies: 
Haemoglobin concentration (Hb), packed cell volume (PCV), red blood cells 
count (RBC), mean corpuscular volume (MCV), and mean corpuscular 
hemoglobin concentration (MCHC), were measured. 
Blood samples were collected into dry clean bottles; the anticoagulant was 
ethylene diamine tetra acetic acid (EDTA). 
 
Red blood cell count (RBCs): 
Total erthrocytes were counted by using Neubauer haemocytometer and Hayem's solution. 
(Kelly, 1984). 
Calculation: 
200 × 50 × R cells = 10.000 × R μl. 
 
Haemoglobin concentration (Hb): 
The concentration of Hb was measured by the cyanmethaemoglobin method (Kelly, 1984). 
The procedure consists of adding 20 μl of blood to 5 ml of a modified Drabkin's solution. After 
10 min the solution of cyanmethaemoglobin is compared against a standard in either 
spectrophotometer (wavelength 540 nm). 
7.5.4. Assessment of hepatoprotective activity  
After 24 h of ethanol administration, on 22nd day, blood was obtained from animals by 
puncturing retro orbital plexus. Blood samples were allowed to clot for 45 min at room 
temperature. Serum was separated by centrifugation at 2500 rpm at 30°C for 15 min and utilized 
for the estimation of various biochemical parameters including SGOT & SGPT (Reitman et al., 
1957), ALP (Kind et al., 1954), serum bilirubin (Amour et al., 1965) and serum protein (Lowry 
et al., 1951) After collection of blood samples, the animals were sacri-ficed under deep ether 
anesthesia. Morphological parameters like weight of animals, weight of liver have also been used 
to evaluate the protective effect of the drug. Hepatoprotective chemical causes loss in liver 
weight/100 gm body weight of rats (Avadhoot et al., 1991; Bhanwra et al., 2000). 
6.5.5. Histopathological studies of the liver in paracetamol induced hepatotoxicity  
  The histopathological evaluation of paracetamol toxicity in all the groups was 
examined and shown in figure. The description is as follows, Section of rat liver treated with 
vehicle control group shows liver parenchyma with intact architecture which is the normal 
appearance. Section of liver in toxicant control group shows partially effaced architecture. Some 
of the hepatocytes show apoptotic changes, perivenular mononuclear inflammatory infiltration, 
scattered inflammatory infiltration within the  parenchyma which is due to toxicity. Section of 
liver in silymarin treated group shows liver parenchyma with intact architecture. Some of the 
central veins show congestion with diffuse congestion of sinusoids.  
  Section of liver in test drug ethanolqueous treated groups shows intact 
architecture, few regenerative hepatocytes, sinusoidal congestion and scattered  mononuclear 
inflammatory cells which is similar to silymarin treated group. 
 
 
  
 
 
Fig : 1 Normal Contol group, showing normal hepatocytes. 
 
 
Fig :2 Ethanol treated animal group shows that hepatic cells damage and congestion of the liver. 
 
 
 
  
 
 
Fig 12 : Hepatocytes in group treated with Standard (Silymarin 200 mg/kg) 
 
Fig 13 : EEBR of 400 mg/kg shows that few regenerative hepatocytes, sinusoidal congestion and 
scattered  mononuclear inflammatory cells 
 
 
 
 
  
 
 
 
 
Fig 14: EEBR of 200 mg/kg shows that few regenerative hepatocytes, sinusoidal congestion and 
scattered  mononuclear inflammatory cells 
 
 
 
 
 
 
 
 
 
8. RESULTS AND DISCUSSION 
Nature of phytoconstituents present in the Basella rubra 
 
1 Test Result 
2 CARBOHYDRATES + 
3 ALKALOIDS - 
4 GUMS AND MUCILAGES + 
5 SAPONINS 
+ 
6 FIXED OILS AND FATS 
- 
7 TANNINS 
- 
8 STARCH 
+ 
9 PROTEINS AND AMINO ACIDS 
+ 
10 PHYTOSTEROLS 
- 
11 PHENOLS 
+ 
12 GLYCOSIDES 
- 
13 REDUCING SUGAR + 
 
( + ) = indicates the presence of constituents,    (-) = indicates the absence of constituents 
 
 TLC of ethanol extract of Basella rubra leaves. 
 
                                 Distance travelled by the solute 
Rf value     =              
   Distance travelled by the solvent 
 
                           =      5.6/10 =   0.56 
 
 
 
Rf values of ethanolic extracts of Basella rubra leaves   
S.No Extract Rf value 
1 EEBR 0.56 
 
 
 
Table 4: Effect of extracts of Ethanolic extract Basella rubra leaves on SGOT 
GROUP 
SGOT level 
mean ± SEM 
Control 1760±1.02 
Negative Control 2097.90± 2.468**a 
Standard 1759.53±2.33**b 
EEBR 200mg/kg 1735.64±1.73
 
*b  
EEBR 400mg/kg 1750.26±1.99
 
***b 
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2.Graphical representation of Effect of EEBR on SGOT 
Values are expressed as Mean ± SEM, n=6 
Comparison: a -Group I vs. Group II  
                       b- Group II vs. Group III, IV & V; NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet‟s “t” Test 
EFFECT OF EEBR ON SGOT 
There was significant (p<0.001) increase in serum SGOT in Ethanol induced group when 
compared to control group. There was significant (p<0.001) decrease in serum SGOT in 
Silymarin treated group when compared to control group. There was significant (p<0.001) 
decrease in serum SGOT in EEBR treated group at a dose of 200mg/kg/p.0 when compared to 
control group. There was significant (p<0.001) decrease in serum SGOT in EEBR treated group 
at a dose of 400mg/kg/p.o when compared to control group. 
    There was a significant (p<0.01) decrease in serum SGOT level in Silymarin treated rats when 
compared to ethanol induced. The EEBR at a dose of 200mg/kg/p.o showed a significant 
(p<0.010) decrease in serum SGOT level when compared to ethanol induced group. The EEBR 
at a dose of 400 mg/kg/p.o showed a significant (p<0.001) decrease in serum SGOT level when 
compared to Ethanol induced group. 
The results were shown in the Table no.4 and Graph no.5. 
Table 5: Effect of extracts of Ethanolic extract Basella rubra leaves on SGPT 
GROUP 
SGPT level  
mean ± SEM 
Control 1875±2.11 
Negative Control 2263.36± 1.46**a 
 Standard 1870.98± 2.65*b 
EEBR 200mg/kg  1883.34±2.22**b 
EEBR 400mg/kg 2090.66± 2.32**b 
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3. Graphical representation of Effect of EEBR on SGPT 
Values are expressed as Mean ± SEM, n=6 
Comparison: a -Group I vs. Group II  
                       b- Group II vs. Group III, IV & V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet‟s “t” Test 
EFFECT of EEBR on SGPT 
 There was significant (p<0.01) increase in serum glutamic pyruvate transaminase level in 
Ethanol induced rats when compared to control group. There was significant (p<0.05) decrease 
in SGPT in ethanol treated group when compared to control group. 
There was significant (p<0.01) decrease in serum SGPT in EEBR treated group at a dose of 
200mg/kg/p.0 when compared to control group. There was significant (p<0.01) decrease in 
serum SGPT in EEBR treated group at a dose of 400mg/kg/p.o when compared to control group. 
    There was a significant (p<0.01) decrease in serum SGPT level in Silymarin treated rats when 
compared ethanol induced group. The EEBR at a dose of 200mg/kg/p.o showed a significant 
(p<0.01) decrease in serum SGOT level when compared to Ethanol induced group. The EEBR  
at a dose of 400 mg/kg/p.o showed a significant (p<0.001) decrease in serum SGOT level when 
compared to Ethanol induced group. 
The results were shown in the Table no 4. And Graph 3.  
 Table 5: Effect of extracts of Ethanolic extract Basella rubra leaves on Bilirubin 
GROUP 
Total Bilirubin  
mean ± SEM 
Control 1.48±0.01 
Negative 
Control 
2.61 ± 0.16***a 
Standard 1.47 ± 0.01*b 
EEBR 
200mg/kg 
1.82 ± 0.03
 
**b 
EEBR 
400mg/kg 
1.53 ± 0.01
 
**b 
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4.Graphical representation of Effect of EEBR on Bilirubin 
Values are expressed as Mean ± SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV & V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet‟s “t” Test 
EFFECT OF EEBR ON TOTAL BILIRUBIN 
There was significant (p<0.01) increase in Bilirubin level in Ethanol induced group when 
compared to control group. There was significant (p<0.01) decrease in Bilirubin in Silymarin 
treated group when compared to control group. There was significant (p<0.05) decrease in 
Bilirubin in EEBR treated group at a dose of 200mg/kg/po when compared to control group. 
There was significant (p<0.001) decrease in Bilirubin in EEBR  treated group at a dose of 
400mg/kg/p.o when compared to control group. 
    There was a significant (p<0.01) decrease in Bilirubin in Silymarin treated rats when 
compared ethanol treated. The EEBR at a dose of 200mg/kg/p.o showed a significant (p<0.05) 
decrease in serum bilirubin when compared to ethanol induced group. The EEBR at a dose of 
400 mg/kg/p.o showed a significant (p<0.001) decrease in Bilirubin when compared to Ethanol 
induced group.  
The results were shown in the Table no5. and Graph no.4.  
 
 
 
 
 
 
Table 6: Effect of extracts of Ethanolic extract Basella rubra leaves on ALP 
GROUP 
ALP level 
mean ± SEM 
Control 35.06±0.12 
Negative Control 53.47±0.01*a 
Standard 37.8±0.03**b 
EEBR 200mg/kg 35±0.72
 
***b 
EEBR 400mg/kg 39.98±0.11*b 
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5. Graphical representation of Effect of EEBR on ALP 
 
Values are expressed as Mean ± SEM, n=6 
Comparison: a -Group I vs Group II  
                       b- Group II vs Group III,  IV & V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet‟s “t” Test 
EFFECT OF EEBR ON ALP 
There was significant (p<0.01) increase in ALP in ethanol induced group when compared to 
control group. There was significant (p<0.01) decrease in ALP in Silymarin treated group when 
compared to control group. There was significant (p<0.05) decrease in ALP  in EEBR treated 
group at a dose of 200mg/kg/p.0 when compared to control group. There was significant 
(p<0.001) decrease in Alp in EEBR treated group at a dose of 400mg/kg/p.o when compared to 
control group. 
 There was a significant (p<0.05) decrease in ALP in Silymarin treated rats when 
compared ethanol treated. The EEBR at a dose of 200mg/kg/p.o showed a significant (p<0.001) 
decrease in ALP when compared to Ethanol induced group. The EEBR at a dose of 400 
mg/kg/p.o showed a significant (p<0.05) decrease in ALP when compared to Ethanol induced 
group.  
The results were shown in the Table no6. and Graph no.5.  
 
 
 
 
 
 
 
 
 8. DISCUSSION 
There are many factors which are responsible for the liver damage or injuries such as chemicals 
and drugs. In the present study ethanol was used to induce Hepatotoxicity, since it is clinically 
relevant. Ethanol produces a constellation of dose related deleterious effects in the liver (Leo et 
al., 1982). The majority of ethanol is metabolized in the liver and individuals who abuse alcohol 
by routinely drinking 50-60 g (about 4 to 5 drinks) of ethanol per day are at risk for developing 
alcoholic liver disease (Zakhari et al., 2007). In addition, both acute and `chronic ethanol 
administration cause enhanced formation of cytokines, especially TNF-alpha by hepatic Kupffer 
cells, which have a significant role in liver injury (Zhou et al., 2003; Thurman et al., 1998; 
Tsukamoto et al., 2001). Besides the development of fatty liver (steatosis), another early sign of 
excessive ethanol consumption is liver enlargement and protein accumulation, both of which are 
common findings in alcoholics and heavy drinkers (Baraona et al., 1975; Baraona et al., 1977).  
Basella rubra are commonly used in the native system of medicine. Various parts of the plant 
like leaves and roots are medicinally important. 
In order to investigate the medicinal use of Basella rubra in hepatoprotective, we evaluated 
crude extract for its Hepatoprotective activity using different in vitro assays and in vivo rat model 
of Hepatoprotective activity 
Preliminary Phytochemical analysis of ethanolic extract of Basella rubra had showed the 
presence of Phytoconstituents like alkaloids, flavonoids, tannins, saponins and Cardiac 
glycosides. Flavanoids and alkaloids are widely distributed in the plant which has the property to 
cure Hepatoprotective activity. Due to this reason the plant has chosen to this study.  This shows 
that the EEBR may contain substances that inhibit liver damage and thus preventing a critical 
step in Hepatotoxicity  
 Elevated levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic 
pyruvic transaminase (SGPT) are indications of hepatocellular injury (Yue et al., 2006). In the 
present study AEAC and AQEAC at a dose of 500 mg/kg, p.o caused a significant inhibition in 
the levels of SGOT and SGPT towards the respective normal range and this is an indication of 
stabilization of plasma membrane as well as repair of hepatic tissue damage caused by ethanol. 
On the other hand suppression of elevated ALP activities with concur-rent depletion of raised 
bilirubin level and an increase in the total plasma protein content suggests the stability of biliary 
dysfunction in rat liver during hepatic injuries with toxicants (Mukherjee et al., 2002). These 
results indicate that AEAC and AQEAC preserved the structural integrity of the hepatocelluar 
membrane and liver cell architecture damaged by ethanol which was confirmed by 
histopathological examination. 
On examining the liver function tests of ethanol induced animals, the SGOT, SGPT, ALP, Total 
bilirubin has significantly increased After treatment with the ethanolic extract of Basella rubra 
(200 mg/kg and 400 mg/kg) the excretion of has SGOT, SGPT, ALP, Total bilirubin 
significantly decreased Although the low dose was more potent than the high dose when 
compared with silymarin treated group, which is a standard. 
Ethanolic extract Basella rubra of has shown promising in vitro efficacy on Hepatoprotective 
activity, we have observed increase in the absorbance indicating the inhibition of Nucleation and 
Aggregation of calcium oxalate in in vitro studies. 
For the in vivo Hepatoprotective activity, of EEBR, Ethanol-induced hepatotoxicity rat model of 
was used. Since the liver damage inducing treatment, Ethanol, was given orally, therefore, the 
extract was given p.o. in order to prevent any potential interaction of Ethanol with plant 
constituents inside gut, interfering with absorption of either of the two. Administration of 
Ethanol resulted in the increased toxicity, which might be due to the Hepatotoxicity, as evident 
by increase in SGOT, SG[T, ALP as compared to norma 
 
 
 
 
 
 
  
 
9. SUMMARY 
  The present study was aimed to assess the hepatoprotective activity and diuretic activity 
of methanolic and aqueous extract of Basella rubra  leaves. LD50 studies were conducted in 
albino rats with aqueous and methanolic extract of  Basella rubra leaves according to OECD 
guideline No.425 and was found safe upto the dose level of 4 gm/kg confirming its non-toxic 
nature. 
HEPATOPROTECTIVE ACTIVITY  
The hepatoprotective activity was studied in ethanol induced hepatotoxic animal model. The 
Physical parameter wet liver weight , Biochemical parameters like serum SGPT, SGOT, and 
total bilirubin levels, and histopathology of livers were considered as major parameters of study.  
  Ethanol induced hepatotoxicity was significantly prevented by pretreatment ethanolic 
extract of leaves. Decrease in wet liver weight, reduction in elevated biochemical parameter 
levels like serum SGPT, SGOT, and total bilirubin, after treatment with ethanolic extract of 
Basella rubra leaves confirmed the hepatoprotective effect of extract under study. In liver injury 
models in rats restoration of hepatic cells with minor fatty changes and absence of necrosis after 
treatment with extract was observed, indicating satisfactory hepatoprotection.  
  Based on improvement in serum marker enzyme levels, physical parameters, and 
histopathological studies it was concluded that ethanol extract of Basella rubra leaves possesses 
significant hepatoprotective activity in the doses used.  
The hepatoprotective activity was studied in ethanol induced hepatotoxic animal model. The 
Physical parameter wet liver weight , Biochemical parameters like serum SGPT, SGOT, and 
total bilirubin levels, and histopathology of livers were considered as major parameters of study.  
 
  
 
10. CONCLUSION 
 HEPATOPROTECTIVE ACTIVITY: 
The hepatoprotective effect of ethanolic extract of basella rubra  leaves was confirmed by the 
following measures: The isolated livers from the toxicant (ethanol) treated animals exhibited 
increase in wet liver weight. Indeed, extract treated animals exhibited decrease in the values of 
above physical parameters as an indication of hepatoprotection. Serum marker enzymes such as 
SGPT, SGOT and total bilirubin,  showed marked increase. The same is observed in liver 
diseases in clinical practice and hence are having diagnostic importance in the assessment of 
liver function. In the present study, the  methanolic and aqueous extract of basella rubra  leaves 
significantly reduced the elevated levels of above mentioned serum marker enzymes. Hence, at 
this point it is concluded that the  methanolic and aqueous extract of basella rubra  leaves 
possesss hepatoprotective activity.   
   In support to this study, histopathological results also show significant activity of the 
plant. In toxicant treated animals there will be severe disturbances in the cytoarchitecture of the 
liver. The same is observed in case of humans who are suffering from major liver disorders. But 
in the methanolic and aqueous extract of basella rubra leaves treated group animals exhibited 
minimal hepatic derangements and intact cytoarchitecture of the liver was maintained. In 
addition to this there is regeneration of hepatocytes also observed, which indicating 
Hepatoprotective activity.   
  Finally based on improvement in serum marker enzyme levels, physical parameters, 
functional parameters and histopathological studies, it is concluded that the  ethanolic extract of 
basella rubra  leaves possesses hepatoprotective activity and thus supports the traditional 
application of the same under the light of modern science.   
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